Methods for generating self-replicating RNA molecules

The method of inserting a polypeptide construct into an alphavirus srRNA vector for srRNA constructs addresses the challenge of insufficient gene product expression, enabling effective in vivo and ex vivo expression of therapeutic polypeptides for immune responses and treatments.

JP2024544623APending Publication Date: 2024-12-03リプリケイト バイオサイエンスインコーポレイティド

Patent Information

Application Number
JP2024531664
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-29
Filing Date
2022-11-28
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Current methods struggle to express gene products, such as therapeutic polypeptides, in vivo or ex vivo in sufficient amounts and times for therapeutic and/or prophylactic benefits using self-replicating RNA (srRNA) constructs.

Method used

A method for identifying and characterizing srRNA constructs by inserting a polypeptide construct of interest (PCI) into an alphavirus srRNA vector, analyzing expression levels and functionality, and incorporating them into delivery vehicles to achieve desired pharmacodynamic effects.

Benefits of technology

Enhances the expression of recombinant polypeptides, such as antigenic and biotherapeutic molecules, in cell culture or in vivo, facilitating immune responses and therapeutic applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544623000001_ABST
    Figure 2024544623000001_ABST
Patent Text Reader

Abstract

The present disclosure generally relates to a novel process for generating self-replicating RNA (srRNA) systems with superior expression characteristics. The present disclosure also provides nucleic acids and recombinant cells expressing such srRNA constructs, as well as pharmaceutical compositions comprising them. Additionally, compositions and methods are provided for inducing a pharmacodynamic effect in a subject, as well as for the prevention and / or treatment of various health conditions.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Application No. 63 / 283,660, filed November 29, 2021. The disclosure of the above application is expressly incorporated by reference in its entirety, including any drawings.

[0002] Field The present disclosure relates to the fields of immunology and medicine, and in particular to a novel process for generating replicons, such as self-replicating RNA (srRNA) molecules, with superior expression characteristics. The present disclosure also provides nucleic acids and recombinant cells expressing such srRNA molecules, as well as pharmaceutical compositions comprising them. Additionally, compositions and methods are provided for inducing a pharmacodynamic effect in a subject, as well as for the prevention and / or treatment of various health conditions.

[0003] Incorporation of sequence listing The material in the attached Sequence Listing is incorporated herein by reference. The attached Sequence Listing text file named 058462-506001WO_Sequence Listing_ST26.xml was created on Nov. 22, 2022 and is 14KB. [Background technology]

[0004] In recent years, several different groups of animal viruses have been subject to genetic engineering, either by homologous recombination or by direct manipulation of the genome. The availability of reverse genetics systems for both DNA and RNA viruses has opened new perspectives for the use of recombinant viruses as, for example, vaccines, expression vectors, antitumor agents, in vivo gene therapy vectors, and drug delivery vehicles.

[0005] Recent developments in this regard include recombinant replicons such as self-replicating RNA (srRNA). These are derived from the genomes of positive-stranded RNA viruses and represent a powerful tool for approaching new safe and effective vaccines and drug delivery vehicles. In particular, srRNA retains the self-replicating activity from RNA viral vectors, and can therefore amplify the amount of RNA encoding a desired gene product by replicating in the host cell, and can be used to increase the efficiency of RNA delivery and / or expression of the encoded gene product for therapeutic and / or prophylactic applications. For example, in vaccine applications, srRNA-based vaccines are beneficial compared to non-replicating RNA (e.g., mRNA) because their self-replicating properties allow for smaller RNA dosages while retaining the advantages of mRNA vaccines, such as rapid development, modular design, and cell-free synthesis. This reduces the manufacturing burden of both drug substance and product, and may be advantageous in terms of pandemic response, as it allows a larger proportion of the population to be vaccinated in a short period of time.

[0006] Although significant advances have been made in srRNA technology in recent years, there remains a need for additional methods to rapidly generate novel srRNA-based expression tools for the in vivo or ex vivo expression of gene products, such as therapeutic polypeptides, in sufficient quantities and for sufficient time to provide therapeutic and / or prophylactic benefit. Summary of the Invention

[0007] The present disclosure generally relates to new methods for identifying and / or characterizing self-replicating RNA (srRNA) constructs, such as replicons, for prophylactic and / or therapeutic use, having superior expression properties suitable for expressing recombinant polypeptides of interest, such as antigenic and biotherapeutic molecules, in cell culture or in vivo. Also disclosed are nucleic acids and recombinant cells expressing such srRNA constructs, as well as pharmaceutical compositions comprising them. Also disclosed herein are methods for inducing a pharmacodynamic effect in a subject, in particular methods for inducing an immune response, and methods for preventing and / or treating a condition in a subject in need thereof. These methods include administering prophylactically or therapeutically one or more of the srRNA constructs, nucleic acid constructs, recombinant cells, and / or pharmaceutical compositions of the present disclosure.

[0008] In one aspect of the disclosure, provided herein is a method for identifying and / or characterizing a self-replicating (srRNA) RNA construct, such as a replicon, comprising: (a) providing a plurality of srRNA expression constructs, each of which comprises a coding sequence for a polypeptide construct of interest (PCI) operably inserted into an alphavirus srRNA vector, wherein at least a portion of the coding sequence for an alphavirus structural protein is replaced with the coding sequence for the PCI; (b) analyzing the level and / or functionality of the PCIs expressed from the plurality of srRNA expression constructs and identifying one or more candidate PCIs having defined properties; (c) incorporating the srRNA expression constructs capable of expressing the candidate PCIs identified in (b) into at least one delivery vehicle to generate a combinatorial collection of delivery systems; and (d) analyzing the delivery systems for their ability to impart at least one pharmacodynamic effect in a subject and identifying srRNA expression constructs capable of imparting a desired pharmacodynamic effect; Includes.

[0009] Non-limiting preferred embodiments of the disclosed methods may include one or more of the following features: In some embodiments, the coding sequence for PCI comprises a coding sequence for a single polypeptide (e.g., monogenic PCI) or a coding sequence for multiple polypeptides (e.g., multigenic PCI). In some embodiments, the coding sequences for the multiple polypeptides are operably linked to each other within a single open reading frame (i.e., within a polycistronic ORF). In some embodiments, the multiple polypeptides are operably linked to each other by one or more connector sequences. In some embodiments, one connector sequence of the multiple connector sequences comprises an autoproteolytic peptide sequence. In some embodiments, the autoproteolytic peptide sequence comprises one or more autoproteolytic cleavage sequences derived from calcium-dependent serine endoprotease (furin), porcine teschovirus-1 2A (P2A), foot-and-mouth disease virus (FMDV) 2A (F2A), equine rhinitis A virus (ERAV) 2A (E2A), Thosea asigna virus 2A (T2A), cytoplasmic polyhedrosis virus 2A (BmCPV2A), flacherie virus 2A (BmIFV2A), or a combination thereof.

[0010] In some embodiments, the coding sequences of the multiple polypeptides are operably linked to one another by one or more internal ribosome entry sites (IRES). In some embodiments, the one or more IRES are selected from a viral IRES, a cellular IRES, and an artificial IRES. In some embodiments, the one or more IRES are selected from a Kaposi's sarcoma-associated herpesvirus (KSHV) IRES, a Hepatitis virus IRES, a Pestivirus IRES, a Cripavirus IRES, a Rhopalosiphum padi virus IRES, a fibroblast growth factor IRES, a platelet-derived growth factor IRES, a vascular endothelial growth factor IRES, an insulin-like growth factor IRES, a picornavirus IRES, an encephalomyocarditis virus (EMCV) IRES, a Pim-1 IRES, a p53 IRES, an Apaf-1 IRES, a TDP2 IRES, an L-myc IRES, and a c-myc IRES.

[0011] In some embodiments, the PCI comprises one or more polypeptides selected from microbial proteins, viral proteins, bacterial proteins, fungal proteins, mammalian proteins, and any combination thereof. In some embodiments, the PCI comprises one or more polypeptides selected from antigenic molecules, biotherapeutic molecules, or any combination thereof. In some embodiments, the PCI comprises one or more antigenic polypeptides selected from tumor-associated antigens, tumor-specific antigens, neoantigens, and any combination thereof. In some embodiments, the one or more antigenic polypeptides comprise estrogen receptors, intracellular signaling enzymes, and human epidermal growth receptors. In some embodiments, the one or more antigenic polypeptides comprise ESR1, PI3K, HER2, HER3, any variants thereof, and any combination thereof. In some embodiments, the PCI comprises one or more biotherapeutic polypeptides selected from immune modulators, regulators of angiogenesis, regulators of extracellular matrix, regulators of metabolism, neuromodulators, and any combination thereof. In some embodiments, the PCI comprises one or more cytokines selected from chemokines, interferons, interleukins, lymphokines, and tumor necrosis factors. In some embodiments, the PCI comprises one or more interleukins selected from IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-15, IL-15, IL-17, IL-23, IL-27, IL-35, IFNγ, and any subunits thereof. In some embodiments, the one or more biotherapeutic polypeptides are selected from IL-12A, IL-12B, IL-1RA, and any combination thereof.

[0012] In some embodiments, step (a) of the methods described herein comprises providing a plurality of srRNA expression constructs, each of which comprises a coding sequence for a variant of PCI. In some embodiments, providing in (a) comprises i) obtaining an alphavirus srRNA expression vector, in which at least a portion of the coding sequence for an alphavirus structural protein has been replaced with a coding sequence for a polypeptide construct of interest (PCI); and ii) generating a plurality of srRNA expression constructs, each of which comprises a coding sequence for a variant of PCI. In some embodiments, providing in (a) comprises i) obtaining coding sequences for a plurality of variants of a polypeptide construct of interest (PCI); and ii) generating a plurality of srRNA expression constructs, each of which comprises the coding sequence for one PCI variant of the plurality of PCI variants from (a), operably inserted into an alphavirus srRNA vector, in which at least a portion of the coding sequence for an alphavirus structural protein has been replaced with a coding sequence for the PCI variant.

[0013] In some embodiments of the methods described herein, a PCI variant of the plurality of PCI variants comprises one or more molecular modifications. In some embodiments, the one or more molecular modifications in the PCI variant are selected from the group consisting of deletions, substitutions, insertions, duplications, mutations, frameshift variants, splice variants, and any combination thereof. In some embodiments, the one or more molecular modifications are configured for a plurality of modification cassettes arranged in tandem along the length of the antigen sequence. In some embodiments, a modification cassette of the plurality of modification cassettes comprises one, two, three, four, five, or more molecular modifications. In some embodiments, the plurality of modification cassettes are operably linked to each other by one or more linkers. In some embodiments, a linker of the one or more linkers comprises a synthetic compound linker or a peptide linker. In some embodiments, the peptide linker comprises an amino acid sequence selected from the group consisting of AAY, EAAAK (SEQ ID NO: 1), RVRR (SEQ ID NO: 2), GGGGS (SEQ ID NO: 3), and GPGPG (SEQ ID NO: 4).

[0014] In some embodiments, the analysis of PCI levels and / or functionality in step (b) is performed in vitro, in vivo, or ex vivo. In some embodiments, the analysis of PCI levels and / or functionality comprises immunoblot analysis, fluorescent flow cytometry analysis, enzyme-linked immunosorbent assay analysis, immunogenicity analysis, bioactivity analysis, and / or efficacy in disease models. In some embodiments, the analysis of the delivery system for its ability to impart at least one pharmacodynamic effect in step (d) is performed in vivo or ex vivo. In some embodiments, the at least one pharmacodynamic effect comprises one or more of an immunogenic effect, a biomarker response, a therapeutic effect, a prophylactic effect, a desirable effect, an undesirable effect, a side effect, and an effect in a disease model. In some embodiments, the at least one pharmacodynamic effect comprises induction of an immune response.

[0015] In some embodiments of the methods described herein, the delivery system comprises a physiological buffer, a liposome, a lipid-based nanoparticle (LNP), a polymeric nanoparticle, a viral replicon particle (VRP), a microsphere, an immune stimulating complex (ISCOM), a conjugate of a bioactive ligand, or any combination thereof. In some embodiments, the LNP delivery system comprises a cationic lipid, an ionizable cationic lipid, an anionic lipid, or a neutral lipid. In some embodiments, the LNP delivery system comprises an ionizable cationic lipid selected from the group consisting of ALC-0315, C12-200, LN16, MC3, MD1, SM-102, and any combination thereof. In some embodiments, the LNP comprises a cationic lipid selected from the group consisting of 98N12-5, C12-200, C14-PEG2000, DLin-KC2-DMA (KC2), DLin-MC3-DMA (MC3), XTC, MD1, 7C1, and any combination thereof. In some embodiments, the LNPs comprise a neutral lipid selected from the group consisting of DPSC, DPPC, POPC, DOPE, SM, and any combination thereof, hi some embodiments, the LNPs comprise a lipid selected from the group consisting of C12-200, C14-PEG2000, DOPE, DMG-PEG2000, DSPC, DOTMA, DOSPA, DOTAP, DMRIE, DC-cholesterol, DOTAP-cholesterol, GAP-DMORIE-DPyPE, and GL67A-DOPE-DMPE-polyethylene glycol (PEG).

[0016] In some embodiments, lipids can be combined in any molar ratio to produce LNPs. Additionally, polynucleotides can be combined with lipids in a wide range of molar ratios to produce LNPs. In some embodiments, the delivery systems described herein include LNPs, and the weight ratio of lipids to nucleic acid in the LNP delivery system is about 100:1 to about 3:1, about 70:1 to 10:1, or about 16:1 to 4:1. In some embodiments, the weight ratio of lipids to nucleic acid in the LNP delivery system is about 16:1 to 4:1. In some embodiments, the weight ratio of lipids to nucleic acid in the LNP delivery system is about 20:1. In some embodiments, the weight ratio of lipids to nucleic acid in the LNP delivery system is about 8:1.

[0017] In some embodiments, lipid-based nanoparticles (LNPs) have an average diameter of less than about 1000 nm, less than about 500 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, less than about 50 nm, or less than about 25 nm. In some embodiments, LNPs have an average diameter in the range of about 70 nm to 100 nm. In some embodiments, LNPs have an average diameter in the range of about 88 nm to about 92 nm, 82 nm to about 86 nm, or about 80 nm to about 95 nm.

[0018] In some embodiments of the methods described herein, the recombinant alphavirus srRNA is from a virus belonging to the genus Alphavirus in the family Togaviridae. In some embodiments, the recombinant alphavirus srRNA is from an alphavirus belonging to the VEEV / EEEV group, or the SFV group, or the SINV group. In some embodiments, the alphavirus is Eastern Equine Encephalitis Virus (EEEV), Venezuelan Equine Encephalitis Virus (VEEV), Everglades Virus (EVEV), Mucambo Virus (MUCV), Pixuna Virus (PIXV), Middleburg Virus (MIDV), Chikungunya Virus (CHIKV), O'Nyong-Nyong Virus (ONNV), Ross River Virus (RRV), Barmah Forest Virus (BHFV), or other alphaviruses. In some embodiments, the alphavirus is selected from the group consisting of BF, Getah virus (GET), Sagiyama virus (SAGV), Bebaru virus (BEBV), Mayaro virus (MAYV), Una virus (UNAV), Sindbis virus (SINV), Aura virus (AURAV), Whataroa virus (WHAV), Babanki virus (BABV), Kyzylagach virus (KYZV), Western Equine Encephalitis virus (WEEV), Highland J virus (HJV), Fort Morgan virus (FMV), Ndumu virus (NDUV), Madariaga virus (MADV), or Buggy Creek virus. In some embodiments, the alphavirus is VEEV, EEEV, CHIKV, or SINV. In some embodiments, the alphavirus is VEEV. In some embodiments, the alphavirus is EEEV. In some embodiments, the alphavirus is CHIKV. In some embodiments, the alphavirus is SINV.

[0019] In some embodiments of the methods described herein, the srRNA expression vector is identified as having immune-inducing activity suitable for prophylactic and / or therapeutic use. In some embodiments, the srRNA expression vector is identified as having immune-inducing activity suitable for prophylactic use. In some embodiments, the srRNA expression vector is identified as having immune-inducing activity suitable for therapeutic use.

[0020] In one aspect, provided herein is a srRNA construct identified according to the methods described herein.

[0021] In another aspect, provided herein are nucleic acids encoding the srRNA constructs described herein.

[0022] In yet another aspect, provided herein is a recombinant cell comprising: (a) an RNA construct as described herein; and / or (b) a nucleic acid as described herein. Non-limiting preferred embodiments of the disclosed methods may include one or more of the following features: In some embodiments, the recombinant cell is a eukaryotic cell. In some embodiments, the recombinant cell is an animal cell. In some embodiments, the animal cell is a vertebrate cell or an invertebrate cell. In some embodiments, the animal cell is a mammalian cell. In some embodiments, the animal cell is an insect cell. In some embodiments, the insect cell is a mosquito cell. In some embodiments, the animal cell is an immune cell. In some embodiments, the immune cell is a B cell, a monocyte, a natural killer (NK) cell, a natural killer T (NKT) cell, a basophil, an eosinophil, a neutrophil, a dendritic cell (DC), a macrophage, a regulatory T cell, a helper T cell (T H ), cytotoxic T cells (T CTL ), memory T cells, gamma delta (γδ) T cells, hematopoietic stem cells, or hematopoietic stem cell precursors. In some embodiments, the immune cell is a B cell, a T cell, or a dendritic cell (DC).

[0023] In a related aspect, provided herein is a cell culture comprising at least one recombinant cell disclosed herein and a cell culture medium.

[0024] In yet another aspect, provided herein are compositions, such as pharmaceutical compositions, that include a therapeutically acceptable excipient; and one or more of: (a) an RNA construct described herein, and / or (b) a nucleic acid described herein, and (c) a recombinant cell described herein.

[0025] Non-limiting preferred embodiments of the compositions described herein may include one or more of the following features: In some embodiments, the composition is formulated as a vaccine. In some embodiments, the composition is formulated as a therapeutic vaccine. In some embodiments, the composition is formulated as an immunogenic composition. In some embodiments, the composition is formulated as a biotherapeutic. In some embodiments, the composition is formulated into a delivery system with a delivery vehicle. In some embodiments, the delivery system comprises a physiological buffer, a liposome, a lipid-based nanoparticle (LNP), a polymeric nanoparticle, a viral replicon particle (VRP), a microsphere, an immune stimulating complex (ISCOM), a conjugate of a bioactive ligand, or any combination thereof. In some embodiments, the LNP delivery system comprises a cationic lipid, an ionizable cationic lipid, an anionic lipid, or a neutral lipid. In some embodiments, the LNP comprises an ionizable cationic lipid selected from the group consisting of ALC-0315, C12-200, LN16, MC3, MD1, SM-102, and any combination thereof. In some embodiments, the LNPs comprise a cationic lipid selected from the group consisting of 98N12-5, C12-200, C14-PEG2000, DLin-KC2-DMA (KC2), DLin-MC3-DMA (MC3), XTC, MD1, 7C1, and any combination thereof. In some embodiments, the LNPs comprise a neutral lipid selected from the group consisting of DPSC, DPPC, POPC, DOPE, SM, and any combination thereof. In some embodiments, the LNPs comprise a lipid selected from the group consisting of C12-200, C14-PEG2000, DOPE, DMG-PEG2000, DSPC, DOTMA, DOSPA, DOTAP, DMRIE, DC-cholesterol, DOTAP-cholesterol, GAP-DMORIE-DPyPE, GL67A-DOPE-DMPE-polyethylene glycol (PEG), and any combination thereof. In some embodiments, the mass ratio of lipid to nucleic acid in the LNP delivery system is about 100:1 to about 3:1, about 70:1 to 10:1, or about 16:1 to 4:1.In some embodiments, the mass ratio of lipid to nucleic acid in the LNP delivery system is about 16:1 to 4:1. In some embodiments, the mass ratio of lipid to nucleic acid in the LNP delivery system is about 20:1. In some embodiments, the mass ratio of lipid to nucleic acid in the LNP delivery system is about 8:1. In some embodiments, the lipid-based nanoparticles (LNPs) have an average diameter of less than about 1000 nm, less than about 500 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, less than about 50 nm, or less than about 25 nm. In some embodiments, the LNPs have an average diameter in the range of about 70 nm to 100 nm. In some embodiments, the LNPs have an average diameter in the range of about 88 nm to about 92 nm, 82 nm to about 86 nm, or about 80 nm to about 95 nm.

[0026] In another aspect, provided herein is a method of inducing a pharmacodynamic effect in a subject, comprising administering to the subject a composition comprising one or more of: (a) an srRNA construct described herein; (b) a nucleic acid described herein; (c) a recombinant cell described herein; and (d) a pharmaceutical composition described herein. In some embodiments, the pharmacodynamic effect comprises eliciting an immune response in the subject. In another aspect, provided herein is a method of preventing or treating a condition in a subject, comprising prophylactically or therapeutically administering to the subject a composition comprising one or more of: (a) an srRNA construct described herein; (b) a nucleic acid described herein; (c) a recombinant cell described herein; and (d) a pharmaceutical composition described herein.

[0027] Non-limiting preferred embodiments of the methods for inducing a pharmacodynamic effect and / or preventing and / or treating a health condition in a subject described herein may include one or more of the following features: In some embodiments, the administered composition induces production of one or more proinflammatory molecules in the subject. In some embodiments, the one or more proinflammatory molecules include interferon gamma (IFNγ), a cytokine, TNF-α, GM-CSF, MIP1α, granzyme B, granzyme A, perforin, or any combination thereof. In some embodiments, the subject has previously been treated with one or more therapies and has acquired at least partial resistance to the one or more therapies. In some embodiments, at least one of the one or more therapies includes a small molecule. In some embodiments, the health condition is a proliferative disease, an inflammatory disease, an autoimmune disease, or a microbial infection. In some embodiments, the subject has or is suspected of having a health condition associated with a proliferative disease, an inflammatory disease, an autoimmune disease, or a microbial infection. In some embodiments, the proliferative disease is cancer. In some embodiments, the cancer is breast cancer. In some embodiments, the compositions are administered to a subject individually as a monotherapy or as a first therapy in combination with at least one additional therapy, which in some embodiments is selected from the group consisting of chemotherapy, radiation therapy, immunotherapy, hormone therapy, toxin therapy, targeted therapy, and surgery.

[0028] In other aspects, provided herein are kits for practicing the methods of the disclosure, e.g., for inducing an immune response and / or for preventing and / or treating a condition, comprising one or more of: (a) an srRNA construct described herein; (b) a nucleic acid described herein; (c) a recombinant cell described herein; and (d) a pharmaceutical composition described herein.

[0029] The foregoing summary is illustrative only and is not intended to be in any way limiting. In addition to the illustrative embodiments and features described herein, further aspects, embodiments, objects, and features of the present disclosure will become more fully apparent from the drawings, detailed description, and claims. [Brief description of the drawings]

[0030] [Figure 1] FIG. 1 is a flow chart illustrating a non-limiting example of a method for identifying and / or characterizing a self-replicating RNA (srRNA) construct according to some embodiments of the present disclosure.

[0031] [Diagram 2] Figure 2 shows the immunogenicity in mice used to optimize the design of mutant ESR1 antigen cassettes. The X-axis shows the ordinality of ESR1 mutations K303R, E380Q, Y537C, Y537S, Y537N, and D538G in the gene cassette, and the use of linkers connecting these mutations. The Y-axis shows the total T cell response when peptides encoding ESR1 sequences are used in an ELISpot assay.

[0032] [Figure 3AB]FIG. 3 shows protein expression from BHK-21 cells transfected with single-, two-, or four-gene srRNA encoding ESR1, PI3K, HER2, and HER3 from a panel of constructs with various molecular configurations, and a comparison of them with the single-gene constructs. The protein expression level of the single-gene constructs is assigned a value of "1" and the relative expression of each gene in the two- or four-gene configuration is compared to the protein expression level of the single-gene constructs. FIG. 3A is an immunoblot of ESR1 protein expression. FIG. 3B is a chart showing relative ESR1 expression based on the signal intensity of the immunoblot bands. FIG. 3C is an immunoblot of PI3K protein expression. FIG. 3D is a chart showing relative PI3K expression based on the signal intensity of the immunoblot bands. Figure 3E is a chart showing the relative expression of HER2 based on mean fluorescence intensity (MFI) quantified by fluorescence flow cytometry (FFC) after staining with a HER2-specific antibody labeled with Alexa Fluor® 488 (AF488). Figure 2E is a chart showing the relative expression of HER3 based on MFI quantified by FFC after staining with a HER3-specific antibody labeled with allophycocyanin (APC). Figure 2G is a spider chart summarizing the protein expression readout of ESR1, PI3K, HER2, and HER3 in the panel of constructs. [Figure 3C-D] Same as above [Fig. 3EF] Same as above [Figure 3G] Same as above

[0033] [Figure 4]Figure 4 is a graphical representation of T cell responses in mice administered constructs with different molecular configurations. The X-axis shows constructs in either monogenic, bigenic or tetragenic form with different orderings of ESR1, PI3K, HER2 and HER3. The Y-axis shows total T cell responses in ELISpot assays against peptides encoding sequences derived from ESR1 mutations, HER2 and HER3. PI3K responses were not measured in this experiment as this does not generate a response in BALB / c mice.

[0034] [Diagram 5] Figure 5 is a schematic diagram of an example of a neoantigen cassette. The peptides containing the mutations are separated by linkers to create a single cassette.

[0035] [Figure 6] Figure 6 graphically depicts T cell responses in mice administered constructs carrying different srRNA vectors formulated in two different lipid nanoparticles, which differ in the cationic lipid in the composition, either LNP1 ("L1") or LNP2 ("L2").

[0036] [Figure 7] FIG. 7 is a schematic illustration of two types of efficacy studies (ie, therapeutic and preventative studies) performed on human disease models against estrogen receptor-positive breast cancer.

[0037] [Figure 8A] Figures 8A-8B are graphical representations of in vitro protein expression from single gene and multigene VEEV srRNA constructs. Protein expression was measured by ELISA using supernatants from BHK-21 cells transfected with each srRNA construct. Figure 8A shows the results of an IL-12 ELISA. The X-axis indicates the various constructs tested. Figure 8B shows the results of an IL-RA ELISA. The X-axis indicates the various constructs tested. [Figure 8B]Same as above

[0038] [Figure 9A] Figures 9A-9B are graphical representations of in vitro bioactivity of proteins from single gene and multi-gene constructs in VEE. Using supernatants from BHK-21 cells transfected with each srRNA construct, cytokine protein bioactivity was measured in reporter cells expressing the relevant receptor. Figure 9A shows the results of an IL-12 bioassay. The X-axis indicates the various constructs tested. Figure 9B shows the results of an IL-1RA bioactivity assay. The X-axis indicates the various constructs tested. [Figure 9B] Same as above

[0039] [Figure 10] FIG. 10 is a graphical representation of the combined IL-12 bioactivity and IL-1RA expression data obtained from the srRNA constructs.

[0040] [Figure 11A] Figures 11A-11B are graphical representations of protein expression from the top two multi-gene constructs cloned into six different srRNA vectors. Figure 11A shows the results of an IL-12 ELISA. The X-axis indicates the various constructs tested. Figure 11B shows the results of an IL-RA ELISA. The X-axis indicates the various constructs tested. [Figure 11B] Same as above

[0041] [Figure 12A] Figures 12A-12B are graphical representations of the biological activity of proteins from the top two multigene constructs cloned into six different srRNA vectors. Figure 12A shows the results of an IL-12 bioassay. The X-axis indicates the various constructs tested. Figure 12B shows the results of an IL-RA bioassay. The X-axis indicates the various constructs tested. [Figure 12B] Same as above

[0042] [Figure 13] FIG. 13 is a graph summarizing IL-12 and IL-1RA bioactivity of the top two multigene constructs in six different srRNA vectors.

[0043] [Figure 14] Figures 14A-14B are graphical representations of in vivo protein expression in mouse serum from the top two bigene constructs in six different srRNA vectors. Figure 14A shows the results of an IL-12 ELISA. The X-axis indicates the various constructs tested. Figure 14B shows the results of an IL-1RA ELISA. The X-axis indicates the various constructs tested.

[0044] [Figure 15] Figures 15A-15B are graphical representations of in vivo protein expression from various formulations of optimal srRNA constructs. Figure 15A shows the results of an IL-12 ELISA. The X-axis indicates the various constructs and formulations tested. Figure 15B shows the results of an IL-RA ELISA. The X-axis indicates the various constructs and formulations tested.

[0045] [Figure 16A] 16A-16B are bar graphs showing the in vivo immunogenicity of a panel of srRNAs encoding the rabies virus envelope glycoprotein G (RABV-G) as an example of a viral antigen. The panel included srRNAs from Venezuelan equine encephalitis virus (VEE.TC83); chikungunya virus strains S27 (CHIK.S27) and DRDE-06 (CHIK.DRDE); Sindbis virus strains Girdwood (SIN.GW) and AR86-Girdwood Hybrid 1 (SIN.AR86); and Eastern equine encephalitis virus (EEE.FL93). FIG. 16A shows antigen-specific splenic T cell responses quantified by ELISpot after two immunizations. FIG. 16B shows anti-rabies neutralizing antibody titers in serum after two immunizations. [Figure 16B] Same as above DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0046] The present disclosure generally relates to novel methods for identifying and / or characterizing self-replicating RNA (srRNA) constructs, such as replicons, for prophylactic and / or therapeutic applications, having superior expression properties suitable for expressing recombinant polypeptides of interest, such as antigenic and biotherapeutic molecules, in cell culture or in vivo. Accordingly, srRNA constructs identified by the methods disclosed herein are also within the scope of the present disclosure. Some aspects and embodiments of the present disclosure relate to recombinant nucleic acids and recombinant cells engineered to express the srRNA constructs disclosed herein, as well as pharmaceutical compositions comprising the same. Some other aspects and embodiments of the present disclosure relate to compositions and methods for inducing a pharmacodynamic effect in a subject, and for the prevention and / or treatment of various health conditions.

[0047] As mentioned above, the recent availability of reverse genetics systems for both DNA and RNA viruses has opened new perspectives for using recombinant viruses as, for example, vaccines, expression vectors, antitumor agents, gene therapy vectors, and drug delivery vehicles. For example, the use of modified viral vectors for gene expression in host cells continues to expand. In particular, many virus-based expression vectors have been deployed to express heterologous proteins in cultured recombinant cells. Recent advances in this regard include further development of techniques and systems for generating multisubunit protein complexes, and co-expression of protein-modifying enzymes to improve heterologous protein production. Other recent advances in viral expression vector technology include the numerous applications of advanced genome engineering for controlling gene expression, preparing viral vectors, in vivo gene therapy applications, and creating vaccine delivery vectors.

[0048] Self-amplifying RNA (srRNA) constructs described herein, upon delivery to, for example, a cell (such as a host cell) or a subject, can amplify themselves and initiate expression and / or overexpression of a heterologous gene product in the host cell or subject. Unlike mRNA, the self-replicating RNA constructs (e.g., replicons) of the present disclosure amplify themselves using their own encoded viral polymerase. Certain srRNA constructs of the present disclosure, such as those based on alphaviruses, can generate large amounts of subgenomic mRNA from which large amounts of heterologous protein can be expressed.

[0049] In some embodiments, the srRNA described herein is based on an RNA virus (e.g., an alphavirus) and can be used as a robust expression system. For example, one advantage of using alphaviruses, such as Chikungunya virus (CHIKV), Eastern Equine Encephalitis virus (EEEV), and Sindbis virus (SINV), as viral expression vectors is reported to be that they can direct the synthesis of large amounts of recombinant protein in recombinant host cells. A particularly significant advantage is that polypeptides such as therapeutic single-chain antibodies may be most effective when expressed at high levels in vivo. Furthermore, when generating recombinant antibodies purified from cells in culture (ex vivo), high expression of proteins from srRNA (e.g., replicons) can increase the overall yield of antibody product. Furthermore, when the protein being expressed is a vaccine antigen, high levels of expression can induce the most robust immune response in vivo.

[0050] In the following detailed description, reference is made to the accompanying drawings, which form a part of this specification. In the drawings, like symbols generally refer to like components unless the context dictates otherwise. The exemplary options set forth in the detailed description, drawings, and claims are not intended to be limiting. Other options may be used and other changes may be made without departing from the spirit or scope of the subject matter presented herein. It will be readily understood that the aspects generally described and illustrated herein can be arranged, substituted, combined, and designed in a wide variety of different configurations, all of which are expressly contemplated and made a part of this application.

[0051] definition Unless otherwise defined, all terms, notations, and other scientific or technical terms used herein are intended to have the meaning commonly understood by those of ordinary skill in the art to which this application pertains. In some cases, terms having a commonly understood meaning are defined herein for clarity and / or ease of reference, and the inclusion of such definitions herein should not necessarily be construed as representing a substantial departure from what is commonly understood in the art. Many of the techniques and procedures described or referenced herein are well understood and commonly employed by those of ordinary skill in the art using conventional methods.

[0052] The singular forms "a," "an," and "the" include plural references unless the context clearly indicates otherwise. For example, the term "a cell" includes one or more cells, and mixtures thereof. "A and / or B" is used herein to mean all of the following alternatives: "A," "B," "A or B," and "A and B."

[0053] It is understood that aspects and embodiments of the disclosure described herein include those that "comprising," "consisting," and "consisting essentially of." As used herein, "comprising" is synonymous with "including," "containing," or "characterized by," and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. As used herein, "consisting" excludes any element, step, or ingredient not specified in the claimed composition or method. As used herein, "consisting essentially of" does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claimed composition or method. Any use of the term "comprising" herein, particularly in describing components of compositions or steps of methods, is understood to include those compositions and methods consisting essentially of, and consisting of, the recited components or steps.

[0054] As used herein, the term "administration" and grammatical variations thereof refer to the delivery of a bioactive composition or formulation by a route of administration, including, but not limited to, intranasal, transdermal, intravenous, intraarterial, intramuscular, intranodal, intraperitoneal, subcutaneous, intramuscular, oral, intravaginal, and topical administration, or combinations thereof. This term includes, but is not limited to, administration by a medical professional and self-administration.

[0055] The terms "cell," "cell culture," and "cell line" refer not only to a particular subject cell, cell culture, or cell line, but also to the progeny or future progeny of such a cell, cell culture, or cell line, regardless of the number of transplants or passages in culture. It should be understood that not all progeny are completely identical to the parent cell, since some modifications may occur in subsequent generations, either due to mutations (e.g., intentional or unintentional mutations) or environmental influences (e.g., methylation or other epigenetic modifications), such that the progeny are not in fact identical to the parent cell. However, so long as the progeny retain the same functionality as the original cell, cell culture, or cell line, they are still included within the scope of the term as used herein.

[0056] The term "construct" refers to a recombinant molecule, such as one or more nucleic acid or amino acid sequences, derived from a heterologous source, e.g., a recombinant nucleic acid or polypeptide. For example, a polypeptide construct can be a chimeric polypeptide molecule, in which two or more amino acid sequences of different origins are operably linked to each other in a single polypeptide construct. Similarly, a nucleic acid construct can be a chimeric nucleic acid molecule, in which two or more nucleic acid sequences of different origins are combined into a single nucleic acid molecule. Exemplary nucleic acid constructs can include any recombinant nucleic acid molecule, including linear or circular, single-stranded or double-stranded DNA or RNA nucleic acid molecules, derived from any source, such as plasmids, cosmids, viruses, autonomously replicating polynucleotide molecules, phages, and capable of genomic integration or self-replicating, with one or more nucleic acid sequences operably linked thereto. In some embodiments, one or more nucleic acid constructs can be incorporated (e.g., inserted) into a single nucleic acid molecule, such as a single vector, or can be incorporated (e.g., inserted) into two or more separate nucleic acid molecules, such as two or more separate vectors. As used herein, the term "vector" refers to a nucleic acid molecule or sequence capable of transferring or transporting other nucleic acid molecules. Thus, the term "vector" encompasses both DNA-based and RNA-based vectors. The term "vector" includes cloning and expression vectors, as well as viral and integrating vectors. An "expression vector" is a vector that includes a regulatory region, thereby allowing expression of DNA sequences and fragments in vitro, ex vivo, and / or in vivo. In some embodiments, a vector may include sequences that direct autonomous replication in a cell, such as, for example, a plasmid (DNA-based vector) or a self-replicating RNA vector. In some embodiments, a vector may include sequences sufficient to allow integration into host cell DNA. In some embodiments, a vector may include a DNA sequence that can be transcribed into RNA in vitro and / or in vivo.Useful vectors include, for example, plasmids (e.g., DNA or RNA plasmids), transposons, cosmids, bacterial artificial chromosomes, and viral vectors. In some embodiments, the vectors of the present disclosure can be single-stranded vectors (e.g., ssDNA or ssRNA). In some embodiments, the vectors of the present disclosure can be double-stranded vectors (e.g., dsDNA or dsRNA). In some embodiments, the vectors are gene delivery vectors. In some embodiments, the vectors are used as gene delivery vehicles to introduce genes into cells. In some embodiments, the vectors of the present disclosure are self-replicating RNA (srRNA) vectors.

[0057] The terms "effective amount," "therapeutically effective amount," or "pharmaceutical effective amount" of a composition, such as an srRNA construct, a nucleic acid construct, a recombinant cell, and / or a pharmaceutical composition of the present disclosure generally refer to an amount sufficient for the composition to achieve a stated purpose (e.g., achieve the intended effect of administration, stimulate an immune response, prevent or treat a disease, or alleviate one or more symptoms of a disease, disorder, infection, or condition) compared to the absence of the composition. An example of an "effective amount" is an amount sufficient to contribute to the treatment, prevention, or alleviation of one or more symptoms of a disease, which may also be referred to as a "therapeutically effective amount." "Alleviation" of a symptom refers to a decrease in the severity or frequency of one or more symptoms, or the elimination of one or more symptoms. The precise amount of a composition that comprises a "therapeutically effective amount" will depend on the purpose of the treatment, and can be ascertained by one of ordinary skill in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins).

[0058] The term "naked" as used herein refers to a nucleic acid that is substantially free of other macromolecules, such as lipids, polymers, and proteins. A "naked" nucleic acid, such as a self-replicating RNA (e.g., a replicon), is not formulated with other macromolecules that improve cellular uptake. Thus, naked nucleic acid is not encapsulated, absorbed, or bound to liposomes, microparticles, nanoparticles, cationic emulsions, and the like.

[0059] The term "operably linked" as used herein refers to a physical or functional link between two or more elements, such as between polypeptide sequences or polynucleotide sequences, that allows the elements to operate in an intended manner. For example, when the term "operably linked" is used in the context of the nucleic acid molecules and srRNA constructs described herein, or the coding and promoter sequences in the nucleic acid constructs, it means that the coding and promoter sequences are in frame and appropriately separated in space and distance, thereby allowing the binding of each of the transcription factors or RNA polymerases to affect transcription. It should be understood that operably linked elements can be contiguous or discontinuous (e.g., linked to each other via a linker).

[0060] In the context of a polypeptide construct, "operably linked" refers to a physical connection (e.g., direct or indirect connection) between amino acid sequences (e.g., between different segments, moieties, or domains) to provide a described activity of the construct. In the present disclosure, regions or domains of the constructs of the present disclosure may be operably linked to retain proper folding, processing, targeting, expression, binding, and other functional properties of the construct in a cell. Unless otherwise specified, the segments, moieties, and domains of the constructs of the present disclosure are operably linked to each other. The operably linked segments, moieties, and domains of the constructs disclosed herein may be contiguous or discontinuous (e.g., may be linked to each other via a linker).

[0061] The term "portion" as used herein means a fraction. With respect to a particular structure, such as a polynucleotide sequence, an amino acid sequence, or a polypeptide, the term "portion" may refer to a continuous or discontinuous portion of the structure. For example, a portion of an amino acid sequence includes at least 1%, at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, and at least 90% of the amino acids of the amino acid sequence. Additionally or alternatively, when the portion is a discontinuous portion, the discontinuous portion may be composed of 2, 3, 4, 5, 6, 7, 8, or more portions of a structure (e.g., a domain of a protein), each portion being a continuous element of the structure. For example, the discontinuous portions of an amino acid sequence may consist of 2, 3, 4, 5, 6, 7, 8 or more portions, such as up to 4 portions, within the amino acid sequence, where each portion comprises at least 1, at least 2, at least 3, at least 4, at least 5 consecutive amino acids, at least 10 consecutive amino acids, at least 20 consecutive amino acids, or at least 30 consecutive amino acids within the amino acid sequence.

[0062] The term "pharmaceutically acceptable excipient" as used herein refers to any suitable substance that provides a pharmaceutically acceptable carrier, additive, or diluent for administration of one or more compounds of interest to a subject. Thus, "pharmaceutically acceptable excipient" can include substances that are called pharmaceutically acceptable diluents, pharmaceutically acceptable additives, and pharmaceutically acceptable carriers. As used herein, "pharmaceutically acceptable carriers" include, but are not limited to, physiological saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonicity agents, absorption delaying agents, and the like, that are compatible with pharmaceutical administration. Supplementary active compounds (e.g., antibiotics and additional therapeutic agents) can also be incorporated into the composition.

[0063] The term "recombinant", when used in reference to a cell, nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein, or vector has been modified or produced by human intervention, including, for example, when they have been modified or produced by laboratory methods. Thus, for example, recombinant proteins and nucleic acids include proteins and nucleic acids produced by laboratory methods. Recombinant proteins can include amino acid residues not found in the native (non-recombinant or wild-type) form of the protein, or can include amino acid residues that have been modified, e.g., labeled. The term can include any modification to a peptide, protein, or nucleic acid sequence. Such modifications can include: any chemical modification, e.g., of one or more amino acids, deoxyribonucleotides, or ribonucleotides, of the peptide, protein, or nucleic acid sequence; addition, deletion, and / or substitution of one or more amino acids in a peptide or protein; generation of fusion proteins, including, for example, antibody fragments; and addition, deletion, and / or substitution of one or more nucleic acids in a nucleic acid sequence. The term "recombinant," when used in reference to a cell, is not intended to include naturally occurring cells, but rather encompasses cells that have been engineered / modified to contain or express a polypeptide or nucleic acid that is not present in the cell without the engineering / modification of the cell.

[0064] As used herein, a "subject" or "individual" includes animals, such as humans (e.g., human individuals) and non-human animals. In some embodiments, a "subject" or "individual" is a patient receiving medical treatment from a physician. Thus, a subject may be a human patient or an individual who has, is at risk of, or is suspected of having a health condition of interest (e.g., cancer or an infectious disease) and / or one or more symptoms of said health condition. A subject may also be an individual who has been diagnosed at or after diagnosis as being at risk for a health condition and / or disease of interest. The term "non-human animal" includes all vertebrates, including mammals, such as rodents, e.g., mice, livestock, domesticated animals and pets, non-human primates, and other mammals, such as sheep, cats, dogs, cows, and chickens; and non-mammals, such as amphibians and reptiles.

[0065] Where a range of values ​​is provided, each intervening value between the upper and lower limit of that range, to one-tenth of the unit of the lower limit unless the context clearly dictates otherwise, is understood to be encompassed within the disclosure, as well as any other stated or intervening value within that stated range. The upper and lower limits of these smaller ranges may independently be included within those smaller ranges, and are also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.

[0066] In this specification, the word "about" is used before a numerical value to indicate a particular range. In this specification, the word "about" is used to literally support the exact number that follows it, and the number that is close or approximate to the number that follows it. When determining whether a number is close or approximate to a specifically indicated number, the close or approximate number may be a number that provides a substantially equivalent number to the specifically indicated number in the context in which the number is provided. If the degree of approximation is not clear from the context, "about" means either within 10% above or below the provided value, or a value rounded to the nearest significant figure, in both cases including the provided value. In some embodiments, the word "about" refers to the specified value ±10%, ±5%, or ±1%.

[0067] Headings such as (a), (b), (i), etc. are provided merely for ease of reading of the specification and claims. The use of headings in the specification or claims does not require that the steps or elements be performed in alphabetical, numerical, or other order as presented.

[0068] It is understood that aspects and embodiments of the disclosure described herein include those that "comprising," "consisting," and "consisting essentially of." As used herein, "comprising" is synonymous with "including," "containing," or "characterized by," and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. As used herein, "consisting" excludes any element, step, or ingredient not specified in the claimed composition or method. As used herein, "consisting essentially of" does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claimed composition or method. Any use of the term "comprising" herein, particularly in describing components of compositions or steps of methods, is understood to include those compositions and methods consisting essentially of, and consisting of, the recited components or steps.

[0069] All genes, gene names, and gene products disclosed herein are intended to correspond to homologs from any species to which the compositions and methods disclosed herein are applicable. Thus, the term includes, but is not limited to, genes and gene products from humans and mice. Where a gene or gene product from a particular species is disclosed, it is understood that the disclosure is intended to be merely exemplary and is not to be construed as limiting unless the context in which it appears clearly indicates otherwise. Thus, for example, the genes or gene products disclosed herein, although in some embodiments related to mammalian nucleic acid and amino acid sequences, are intended to encompass homologous and / or orthologous genes and gene products from other animals, including, but not limited to, other mammals, fish, amphibians, reptiles, and birds. In some embodiments, the genes, nucleic acid sequences, amino acid sequences, peptides, polypeptides, and proteins are human. The term "gene" is also intended to include variants thereof.

[0070] It is understood that although certain features of the present disclosure are described for clarity in the context of separate embodiments, they may also be provided in combination in a single embodiment. Conversely, various features of the present disclosure that are described for brevity in the context of a single embodiment may also be provided separately or in any suitable sub-combination. All combinations of the embodiments according to the present disclosure are specifically embraced by the present disclosure and are disclosed herein as if each and every combination were individually and explicitly disclosed. Moreover, all subcombinations of the various embodiments and elements are specifically embraced by the present disclosure and are disclosed herein as if each and every such subcombination were individually and explicitly disclosed herein.

[0071] Alphaviruses Alphaviruses are small, enveloped RNA viruses with a single positive-stranded RNA genome. The alphavirus genus includes, among others, Sindbis virus (SINV), Semliki Forest virus (SFV), Ross River virus (RRV), Venezuelan equine encephalitis virus (VEEV), and Eastern equine encephalitis virus (EEEV), which are closely related and can infect a variety of vertebrates, including mammals, rodents, fish, birds, and larger mammals such as humans and horses; as well as invertebrates such as insects. In particular, Sindbis virus and Semliki Forest virus have been extensively studied, and the life cycle and replication patterns of these viruses are well characterized.Non-limiting examples of alphavirus species suitable for the compositions and methods disclosed herein include Aura virus (AURAV), Babanki virus (BABV), Barmah Forest virus (BFV), Bebaru virus (BEBV), Buggy Creek virus, Caaingua virus, Cabassou virus, Chikungunya virus (CHIKV), Eastern Equine Encephalitis virus (EEEV), Eilat virus, Everglades virus (EVEV), Fort Morgan virus (FMV), Getah virus (GETV), Highland J virus (HJV), Kizilagak virus (KYZV), Madariaga virus (MADV), Mayaro virus (MAYV), Middelburg virus (MIDV), Mosso das Pedras virus (Mo ... Pedras virus, Mucambo virus (MUCV), Nudum virus (NDUV), Onyong-nyong virus (ONNV), Pixuna virus (PIXV), Rio Negro virus (RNV), Ross River virus (RRV), Salmon pancreas disease virus (SPDV), Semliki Forest virus (SFV), Sindbis virus (SINV), Sleeping sickness virus (SDV), Southern elephant seal virus (SESV), Tai Forest virus (TFV), Tonate virus, Trocara virus, Una virus (UNAV), Venezuelan equine encephalitis virus (VEEV), Western equine encephalitis virus (WEEV), and Wataroa virus (WHAV).

[0072] The alphavirus genome is approximately 12 kb in length and consists of two open reading frames (ORFs): a 7 kb frame encoding the nonstructural proteins (nsPs) and a 4 kb frame encoding the structural polyprotein. The nonstructural polyprotein (nsP) is cleaved inside the host cell cytoplasm into four distinct proteins (nsP1, nsP2, nsP3, and nsP4) required for the transcription and translation of viral mRNA.

[0073] The nsP1 protein is an mRNA capping enzyme with both guanine-7-methyltransferase (MTase) and guanylyltransferase (GTase) activities that directs the methylation and capping of newly synthesized viral genomic and subgenomic RNA. The MTase motif in the N-terminal domain of nsP1 catalyzes the transfer of a methyl group from S-adenosylmethionine (AdoMet) to the N7 position of a GTP molecule (m7Gppp). The GTase then binds m7Gppp and forms a covalent bond with the catalytic histidine (m7Gp-GTase), releasing PPi. The GTase then transfers the m7Gp molecule to the 5'-diphosphate RNA, generating m7GpppNp-RNA. The resulting cap structure is essential for the translation of viral mRNA and protects the mRNA from being degraded by cellular 5' exonucleases. Following the N-terminal domain are features that allow the binding of the nsP1 protein to the cell membrane. The presence of the α-helical amphipathic loop and the palmitoylation site anchors the nsP1 protein, and replication complexes containing nsP1, on the plasma membrane, presumably via interactions of nsP1 with anionic membrane phospholipids.

[0074] The nsP2 protein has many enzymatic activities and functional roles. The N-terminal region contains a helicase domain with seven signature motifs of superfamily 1 (SF1) helicases. It functions as an RNA triphosphatase responsible for the initiation of the viral RNA capping reaction. It also functions as a nucleotide triphosphatase (NTPase) and promotes the RNA helicase activity. The C-terminal region of nsP2 contains a papain-like cysteine ​​protease, which is involved in processing the viral nonstructural polyprotein. This proteolytic function is highly regulated and is modulated by other domains of nsP2. Alphavirus nsP2 proteins have also been described as virulence factors involved in halting transcription and translation in infected host cells and inhibiting interferon (IFN)-mediated antiviral responses, contributing to the regulation of the translation machinery by viral factors.

[0075] The exact role of the alphavirus nsP3 protein in the replication complex is less clear. The nsP3 protein contains three domains: an N-terminal macrodomain with phosphatase activity and nucleic acid binding capacity, an alphavirus unique domain (AUD), and a C-terminal hypervariable domain. Deletion of this domain in SFV nsP3 has been shown to reduce viral pathogenicity, suggesting its importance in regulating viral RNA transcription.

[0076] The nsP4 polymerase is the most conserved protein in alphaviruses, with the most divergent amino acid sequence identities of over 50% when compared with nsP4 from other alphaviruses. nsP4 contains a core RNA-dependent RNA polymerase (RdRp) domain at the C-terminus that is known to be solely responsible for the RNA synthesis properties of the viral replication complex. RdRp is involved in the replication of genomic RNA via negative-strand RNA and in transcription of the 26S subgenomic RNA. The N-terminal domain is alphavirus-specific and may have a partially disordered structure.

[0077] The 5' two-thirds of the alphavirus genome encodes several nonstructural proteins (nsPs) necessary for viral RNA transcription and replication. These proteins are directly translated from RNA and, together with cellular proteins, form the RNA-dependent RNA polymerase that is essential for viral genome replication and subgenomic RNA transcription. Four nonstructural proteins (nsP1, nsP2, nsP3, and nsP4) are produced as a single polyprotein and constitute the viral replication machinery. Polyprotein processing occurs in a highly regulated manner, and cleavage at the P2 / 3 junction affects the availability of the RNA template during genome replication. This site is located at the bottom of a narrow cleft and is not easily accessible. Once cleaved, nsP3 generates a ring structure that surrounds nsP2. These two proteins have an extensive interface. Mutations in nsP2 that produce noncytopathic viruses or temperature-sensitive phenotypes are clustered in the P2 / P3 interface region. P3 mutations located opposite the noncytopathic mutations in nsP2 prevent efficient cleavage of P2 / 3. This may ultimately affect RNA infectivity and alter the levels of viral RNA production.

[0078] The 3' third of the genome contains the subgenomic RNA that serves as a template for the translation of all structural proteins required for the formation of viral particles, namely the core nucleocapsid protein C, and the envelope proteins P62 and E1, which assemble as a heterodimer. Surface glycoproteins, anchored in the viral membrane, are involved in receptor recognition and entry into target cells by membrane fusion. The subgenomic RNA is transcribed from the p26S subgenomic promoter located at the 3' end of the RNA sequence encoding the nsP4 protein. Proteolytic maturation of P62 into E2 and E3 causes changes in the viral surface. Together, the glycoprotein "spikes" of E1 and E2, and possibly E3, form E1 / E2 dimers or E1 / E2 / E3 trimers, in which E2 extends from the center to the apexes, E1 fills the space between the apexes, and E3, if present, is located at the distal end of the spike. When the virus is exposed to the acidic environment of the endosome, E1 dissociates from E2 to form the E1 homotrimer, which is required for the fusion step between the cellular and viral membranes. The alphavirus glycoprotein E1 is a class II viral fusion protein that is structurally distinct from the class I fusion proteins found in influenza viruses and HIV. The E2 glycoprotein functions to interact with the nucleocapsid via its cytoplasmic domain, while its extracellular domain is responsible for binding to cellular receptors. Most alphaviruses have lost the peripheral protein E3, but in Semlikivirus E3 remains associated with the viral surface.

[0079] Alphavirus replication has been reported to occur on the membrane surface within the host cell. In the first step of the infection cycle, the 5' end of the genomic RNA is translated into polyproteins (nsP1-4) with RNA polymerase activity, which generate a minus strand complementary to the genomic RNA. In the second step, two RNAs are generated using the minus strand as a template: (1) a positive-strand genomic RNA, which corresponds to the genome of a secondary virus, which translates to produce other nsPs and serves as the genome for the virus, and (2) a subgenomic RNA, which codes for the viral structural proteins that form the infectious particle. The ratio of positive-strand genomic RNA / subgenomic RNA is controlled by the proteolytic autocleavage of the polyprotein to nsP1, nsP2, nsP3, and nsP4. In reality, viral gene expression occurs in two phases. In the first phase, the primary synthesis of the positive and negative strands occurs. In the second phase, the synthesis of the subgenomic RNA is virtually exclusive, resulting in the production of large amounts of structural proteins.

[0080] self-replicating RNA As will be understood by those skilled in the art, the term "self-replicating RNA" refers to an RNA molecule that contains all of the genetic information necessary to direct its own amplification or self-replication in a permissive cell. Therefore, srRNA may also be referred to as "self-amplifying RNA" (saRNA). In some embodiments, srRNA is a "replicon," which can be a linear or circular piece of DNA or RNA that is sequentially replicated as a unit. Non-limiting examples of replicons include "replicon RNA" or "RNA replicon." To direct its own replication, srRNA typically (1) encodes a polymerase, replicase, or other protein that can interact with viral or host cell-derived proteins, nucleic acids, or ribonucleoproteins to catalyze the RNA amplification process, and (2) contains cis-acting RNA sequences necessary for the replication and transcription of the RNA encoded by the subgenomic replicon. These sequences may bind to proteins that they themselves encode or to non-encoded cellular proteins, nucleic acids, ribonucleoproteins, or complexes between any of these components during replication. In some embodiments of the present disclosure, the replicon, e.g., srRNA (such as a replicon), is derived from an alphavirus. In some embodiments of the present disclosure, an alphavirus srRNA construct (e.g., srRNA, saRNA, or replicon molecule) typically includes the following elements: a 5' viral RNA sequence or defective-interfering RNA sequence required in cis for replication, sequences encoding biologically active alphavirus nonstructural proteins (e.g., nsP1, nsP2, nsP3, and nsP4), a subgenomic promoter (sg) for the subgenomic RNA (sgRNA), 3' viral sequences required in cis for replication, and, optionally, a polyadenylic acid tract (poly(A)). In some examples, a subgenomic promoter (sg) directing expression of a heterologous sequence may be included in the srRNA construct of the present disclosure.

[0081] Additionally, the term srRNA molecule (e.g., srRNA, saRNA, or replicon molecule) generally refers to a molecule of positive polarity, or "message" sense, and the srRNA may be of a different length than any known naturally occurring alphavirus. In some embodiments of the present disclosure, the srRNA does not contain at least a portion of the coding sequence for one or more alphavirus structural proteins; and / or the sequence encoding the structural genes may be replaced by a heterologous sequence. In these instances, when the srRNA is packaged into recombinant alphavirus particles, the srRNA may contain one or more sequences, so-called packaging signals, that serve to initiate interactions with alphavirus structural proteins resulting in particle formation.

[0082] The srRNA constructs of the present disclosure typically have a length of at least about 2 kb. For example, the srRNA can have a length of at least about 2 kb, at least about 3 kb, at least about 4 kb, at least about 5 kb, at least about 6 kb, at least about 7 kb, at least about 8 kb, at least about 9 kb, at least about 10 kb, at least about 11 kb, at least about 12 kb, or more than 12 kb. In some embodiments, the srRNA is about 4 kb to about 20 kb, about 4 kb to about 18 kb, about 5 kb to about 16 kb, about 6 kb to about 14 kb, about 7 kb to about 12 kb, about 8 kb to about 16 kb, about 9 kb to about 14 kb, about 10 kb to about 18 kb, about 11 kb to about 16 kb, about 5 kb to about 18 kb, about 6 kb to about 20 kb, about 5 kb to about 10 kb, about 5 kb to about 8 kb, about 5 kb to about 7 kb, about 5 kb to about 6 kb, , about 6 kb to about 12 kb, about 6 kb to about 11 kb, about 6 kb to about 10 kb, about 6 kb to about 9 kb, about 6 kb to about 8 kb, about 6 kb to about 7 kb, about 7 kb to about 11 kb, about 7 kb to about 10 kb, about 7 kb to about 9 kb, about 7 kb to about 8 kb, about 8 kb to about 11 kb, about 8 kb to about 10 kb, about 8 kb to about 9 kb, about 9 kb to about 11 kb, about 9 kb to about 10 kb, or about 10 kb to about 11 kb in length. In some embodiments, the srRNA may have a length of about 6 kb to about 14 kb. In some embodiments, the srRNA may have a length of about 6 kb to about 16 kb.

[0083] Methods for identifying and / or characterizing srRNA constructs As described in more detail below, one aspect of the disclosure relates to methods for identifying and / or characterizing srRNA constructs, including srRNA constructs that have desired expression properties suitable for expressing recombinant polypeptides of interest, such as antigenic and biotherapeutic molecules, in host cells, cell cultures, or ex vivo cell-free expression systems, or suitable for expression in a subject for prophylactic and / or therapeutic applications.

[0084] Figure 1 is a flow chart illustrating a non-limiting example of a method for identifying and / or characterizing a self-replicating RNA (srRNA, such as a replicon) construct disclosed herein. As shown in Figure 1, in some embodiments, the disclosed method can include the following operations: (a) providing a plurality of srRNA expression constructs, each of which comprises a coding sequence for a polypeptide construct of interest (PCI) operably inserted into an alphavirus srRNA vector, wherein at least a portion of the coding sequence for an alphavirus structural protein is replaced with the coding sequence for the PCI; (b) analyzing the level and / or functionality of the PCIs expressed from the plurality of srRNA expression constructs to identify one or more candidate PCIs having defined properties; (c) incorporating the srRNA expression constructs capable of expressing the candidate PCIs identified in (b) into at least one delivery vehicle to generate a combinatorial collection of delivery systems; and d) analyzing the delivery systems for their ability to impart at least one pharmacodynamic effect in a subject, to identify srRNA expression constructs capable of imparting a desired pharmacodynamic effect.

[0085] Non-limiting preferred embodiments of the disclosed methods may include one or more of the following features: In some embodiments, the alphavirus srRNA vector lacks at least a portion of the nucleic acid sequence encoding one or more of the viral structural proteins CP, E1, E2, E3, and 6K of the alphavirus srRNA vector. In some embodiments, the alphavirus srRNA vector lacks some or all of the sequence encoding CP. In some embodiments, the alphavirus srRNA vector lacks some or all of the sequence encoding E1. In some embodiments, the alphavirus srRNA vector lacks some or all of the sequence encoding E2. In some embodiments, the alphavirus srRNA vector lacks some or all of the sequence encoding E3. In some embodiments, the alphavirus srRNA vector lacks some or all of the sequence encoding 6K. In some embodiments, the alphavirus srRNA vector lacks some or all of the sequence encoding a combination of CP, E1, E2, E3, and 6K. In some embodiments of the present disclosure, the coding sequences for the nonstructural proteins nsP1, nsP2, nsP3, and nsP4 of the alphavirus srRNA vector are present, but at least a portion or all of the sequences encoding one or more structural proteins (e.g., CP, E1, E2, E3, and 6K) of the alphavirus srRNA vector are absent.

[0086] In some embodiments, the alphavirus srRNA vector lacks a substantial portion of the nucleic acid sequence encoding one or more viral structural proteins. One of skill in the art will appreciate that a substantial portion of the nucleic acid sequence encoding a viral structural polypeptide may include sufficient nucleic acid sequence encoding a viral structural polypeptide to allow for putative identification of the polypeptide, either by manual evaluation of the sequence by one of skill in the art, or by computer-automated comparison and identification of the sequences using algorithms such as BLAST (e.g., "Basic Local Alignment Search Tool"; see Altschul SF et al., J. Mol. Biol. 215:403-410, 1993). Thus, a substantial portion of a nucleotide sequence includes sufficient sequence to specifically identify and / or isolate a nucleic acid fragment comprising that sequence. For example, a substantial portion of a nucleic acid sequence may include at least about 20%, e.g., about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 95% of the full length nucleic acid sequence.

[0087] In some embodiments, the alphavirus srRNA vector lacks the entire sequence encoding a viral structural protein, e.g., the alphavirus srRNA vector does not include nucleic acid sequences encoding viral structural proteins.

[0088] In some embodiments, the coding sequence for PCI comprises a coding sequence for a single polypeptide (e.g., a monogenic PCI). In some embodiments, the coding sequence for PCI comprises a coding sequence for multiple polypeptides (e.g., a multigenic PCI, such as a bigenic, trigenic, or tetragenic PCI). In some embodiments, the coding sequences for the multiple polypeptides are each operably linked to a separate promoter sequence. In some embodiments, the coding sequences for the multiple polypeptides are operably linked to each other in a single open reading frame (i.e., in a polycistronic ORF). In some embodiments, the coding sequence of the polycistronic ORF is operably linked to a promoter sequence. In some embodiments, at least one of the promoter sequences is a subgenomic (sg) promoter. In some embodiments, the sg promoter is a 26S genomic promoter.

[0089] In some embodiments, the multiple polypeptides may be linked directly to each other or indirectly (e.g., by one or more connector sequences). For example, in some embodiments, the multiple polypeptides may be linked directly to each other, e.g., adjacent to each other. In some embodiments, at least two (e.g., two, three, four, or five) of the multiple polypeptides are operably linked to each other by one or more connector sequences. In some embodiments, the length and amino acid composition of the connector sequences may be optimized to alter the orientation, flexibility, and / or proximity of the polypeptides relative to each other to achieve a desired activity or property of PCI. In some embodiments, a connector sequence of the multiple connector sequences comprises one or more autoproteolytic peptide sequences. Non-limiting examples of autoproteolytic peptide sequences suitable for the methods and compositions of the present disclosure include autoproteolytic sequences derived from calcium-dependent serine endoprotease (furin), porcine teschovirus-1 2A (P2A), foot and mouth disease virus (FMDV) 2A (F2A), equine rhinitis A virus (ERAV) 2A (E2A), tosea asignavirus 2A (T2A), cytoplasmic polyhedrosis virus 2A (BmCPV2A), and flacherie disease virus 2A (BmIFV2A). In some embodiments, at least two of the plurality of polypeptides are operably linked to each other via a P2A autoproteolytic sequence.

[0090] In some embodiments, the coding sequences of the multiple polypeptides are operably linked to each other by one or more internal ribosome entry sites (IRES). Non-limiting examples of IRES suitable for the methods and compositions of the present disclosure include viral IRES sequences, cellular IRES sequences, and artificial IRES sequences. Examples of suitable IRES sequences include, but are not limited to, Kaposi's sarcoma-associated herpesvirus (KSHV) IRES, hepatitis virus IRES, pestivirus IRES, Cripavirus IRES, Rhopalosipum padivirus IRES, fibroblast growth factor IRES, platelet-derived growth factor IRES, vascular endothelial growth factor IRES, insulin-like growth factor IRES, picornavirus IRES, encephalomyocarditis virus (EMCV) IRES, Pim-1 IRES, p53 IRES, Apaf-1 IRES, TDP2 IRES, L-myc IRES, and c-myc IRES.

[0091] Polypeptide construct of interest (PCI) As described in more detail below, a polypeptide construct of interest (PCI) may comprise the amino acid sequence of one or more polypeptides. There is no particular limit in principle as to suitable polypeptides that may be expressed by the srRNA construct of the present disclosure. Examples of types of polypeptides suitable for the compositions and methods of the present disclosure include microbial proteins, viral proteins, bacterial proteins, fungal proteins, mammalian proteins, and any combination thereof. For example, a PCI may comprise one or more antigenic and / or biotherapeutic molecules, such as cytokines, cytotoxins, chemokines, immunomodulatory factors, pro-apoptotic factors, anti-apoptotic factors, hormones, differentiation factors, dedifferentiation factors, immune cell receptors or reporters, or any combination thereof.

[0092] In some embodiments, the PCI may comprise one or more interleukins and interacting proteins, such as G-CSF, GM-CSF, IL-1, IL-10, IL-10-like, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-18BP, IL-1-like, IL-1RA, IL-1α, IL-1β, IL-2, IL-20, IL-3, IL-4, IL-5, IL-6, IL-6-like, IL-7, IL-9, IL-21, IL-22, IL-33, IL-37, IL-38, LIF, and OSM. Further suitable polypeptides include interferons (e.g., IFN-α, IFN-β, and IFN-γ), TNF (e.g., CD154, LT-β, ​​TNF-α, TNF-β, 4-1BBL, APRIL, CD70, CD153, CD178, GITRL, LIGHT, OX40L, TALL-1, TRAIL, TWEAK, and TRANCE), TGF-β (e.g., TGF-β1, TGF-β2, and TGF-β3), hematopoietins (e.g., Epo, Tpo, Flt-3L, SCF, M-CSF, and MSP), chemokines and their receptors (e.g., XCL1, XCL2, CCL1, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL210, CCL220, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CCL29, CCL30, CCL310, CCL320, CCL33, CCL34, CCL35, CCL36, CCL37, CCL38, CCL39 ... CL11, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, and CX3CL1), and immune suppressive gene products and related transcription factors (e.g., PECAM1, FCGR3A, FOS, NFKB1, JUN, HIF1A, PD-L1, mTOR, STAT5B, and STAT4).

[0093] Examples of additional polypeptides suitable for the compositions and methods of the present disclosure include, but are not limited to, immunostimulatory gene products (e.g., CD27 / CD70, CD40, CD40L, B7.1, BTLA, MAVS, OX40, OX40L, RIG-I, and STING); and drug-resistant mutants or variants of genes such as ABCB1, ABCC1, ABCG2, AKT1, ALK, BAFF, BCR-ABL, BRAF, CCND1, cMET, EGFR, ERBB2, ERBB3, ERK2, ESR1, GRB2, KRAS, MDR1, MRP1, NTRK1, PDC4, P-gp, PI3K, PTEN, RET, ROS1, RSK1, RSK2, SHIP, and STK11. Examples suitable for the compositions and methods of the present disclosure also include sequences encoding viral proteins, particularly spike proteins, fiber proteins, structural proteins, and attachment proteins. In some embodiments, the PCT may comprise one or more surface-exposed viral antigens, e.g., surface-exposed viral proteins. In some embodiments, the viral protein is a glycoprotein. In some embodiments, the PCT may comprise a surface glycoprotein. In some embodiments, the viral glycoprotein is a rabies virus glycoprotein. In some embodiments, the viral glycoprotein is the envelope glycoprotein G of rabies virus (RABV-G).

[0094] In some embodiments, the PCI may comprise the amino acid sequence of one or more antibodies or antibody variants (e.g., single chain Fv, bispecifics, camelids, Fab, and HCAb). In some embodiments, the antibody targets a molecule associated with or upregulated in cancer, or a molecule associated with infectious disease. In some embodiments, the antibody targets a molecule with immunostimulatory or immunosuppressive function.

[0095] In some embodiments, the PCI may comprise the amino acid sequence of an enzyme whose deficiency or mutation is associated with a disease or condition, examples of which include agalsidase beta, agalsidase alpha, imiglucerase, taliglucerase alpha, velaglucerase alpha, alglucerase, sebelipase alpha, laronidase, idursulfase, elosulfase alpha, galsulfase, alglucosidase alpha, and CTFR.

[0096] In some embodiments, the PCI may comprise an amino acid sequence of a polypeptide selected from an antigen molecule, a biotherapeutic molecule, or any combination thereof. In some embodiments, the PCI may comprise an amino acid sequence of a polypeptide selected from a tumor associated antigen, a tumor specific antigen, a neoantigen, and any combination thereof. In some embodiments, the PCI may comprise an amino acid sequence of a polypeptide selected from an estrogen receptor, an intracellular signaling enzyme, and a human epidermal growth receptor. In some embodiments, the PCI may comprise an amino acid sequence of a biotherapeutic polypeptide selected from an immunomodulator, an angiogenesis regulator, an extracellular matrix regulator, a metabolic regulator, a neuromodulator, and any combination thereof. In some embodiments, the PCI may comprise an amino acid sequence of a cytokine selected from a chemokine, an interferon, an interleukin, a lymphokine, and a tumor necrosis factor. In some embodiments, the PCI may comprise the amino acid sequence of an interleukin selected from IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-15, IL-15, IL-17, IL-23, IL-27, IL-35, IFNγ, and any subunits thereof. In some embodiments, the PCI may comprise the amino acid sequence of a biotherapeutic polypeptide selected from IL-12A, IL-12B, IL-1RA, and any combination thereof.

[0097] In some embodiments, the PCI may include one or more antigen polypeptides. As mentioned above, there is no particular limit in principle as to suitable antigen polypeptides that may be expressed by the srRNA construct of the present disclosure. Thus, in some embodiments, the PCI may include one or more antigen polypeptides, which may be tumor-associated antigens (TAA), tumor-specific antigens (TSA), neo-antigens, and any combination thereof. As will be understood by those skilled in the art, TAAs include molecules, such as proteins, that are present on tumor cells and on normal cells or on many normal cells, but are much less concentrated on normal cells than on tumor cells. In contrast, TSAs generally include molecules, such as proteins, that are present on tumor cells but not on normal cells. A tumor-associated antigen may be an antigen associated with a cancer cell, such as a breast cancer cell, a B-cell lymphoma, a pancreatic cancer, a Hodgkin's lymphoma cell, an ovarian cancer cell, a prostate cancer cell, a mesothelioma, a lung cancer cell, a non-Hodgkin's B-cell lymphoma (B-NHL) cell, an ovarian cancer cell, a prostate cancer cell, a mesothelioma cell, a melanoma cell, a chronic lymphocytic leukemia cell, an acute lymphocytic leukemia cell, a neuroblastoma cell, a glioma, a glioblastoma, and a colon cancer cell. It is understood that in some cases, a tumor-associated antigen may also be expressed by a non-cancerous cell.

[0098] In some embodiments, examples of the one or more antigenic polypeptides include estrogen receptor, intracellular signaling enzyme, and human epidermal growth receptor. In some embodiments, the one or more antigenic polypeptides are selected from the group consisting of ESR1, PI3K, HER2, HER3, any variants thereof, and any combinations thereof. In some embodiments, the coding sequence of the ESR1 variant comprises one or more molecular modifications that promote ligand-independent receptor activity. In some embodiments, the one or more molecular modifications comprise an activating mutation selected from the group consisting of K303R, E380Q, Y537C, Y537S, Y537N, and D538G. In some embodiments, the coding sequence of the PI3K variant comprises one or more molecular modifications that promote ligand-independent receptor activity. In some embodiments, the one or more molecular modifications comprise an activating mutation selected from the group consisting of E542K, E545K, H1047L, and H1047R. In some embodiments, the HER2 variant comprises a coding sequence for an extracellular domain and a transmembrane domain. In some embodiments, the HER3 variant comprises a coding sequence for a kinase-inactive HER3. In some embodiments, the coding sequence for PCI comprises, from 5'- to 3'-direction, a) a coding sequence for a variant of PI3K comprising one or more activating molecular modifications selected from E542K, H1047L, E545K, and H1047R; b) a coding sequence for the autoproteolytic peptide P2A; c) a coding sequence for a variant of HER2 comprising its extracellular and transmembrane domains; d) a coding sequence for the autoproteolytic peptide P2A; e) a coding sequence for a kinase-inactive variant of HER3; f) a coding sequence for an internal ribosome entry site (IRES); and g) a coding sequence for a variant of ESR1 comprising one or more activating molecular modifications selected from Y537C, E380Q, K303R, Y537S, D538G, and Y537N.

[0099] In some embodiments, the PCI comprises one or more biotherapeutic polypeptides. There are generally no particular limitations regarding suitable biotherapeutic polypeptides that may be expressed by the srRNA constructs of the present disclosure. Examples of biotherapeutic polypeptides suitable for the compositions and methods of the present disclosure include, but are not limited to, immunomodulators, angiogenesis regulators, extracellular matrix regulators, metabolic regulators, neuromodulators, and any combination thereof. In some embodiments, the PCI comprises one or more cytokines. Non-limiting examples of cytokines include chemokines, interferons, interleukins, lymphokines, and tumor necrosis factors. In some embodiments, the PCI comprises one or more interleukins. Suitable interleukins include IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-15, IL-15, IL-17, IL-23, IL-27, IL-35, IFNγ, and any subunits thereof. In some embodiments, the one or more biotherapeutic polypeptides are selected from the p35 subunit of interleukin-12 (p35 or IL-12A), the p40 subunit of interleukin-12 (p40 or IL-12B), interleukin-1 receptor antagonist (IL-1RA), any variants thereof, and any combinations thereof. In some embodiments, a polypeptide construct of interest comprises, from N-terminus to C-terminus, a) an IL-12A polypeptide, an IL-12B polypeptide, and an IL-1RA polypeptide; or b) an IL-1RA polypeptide, an IL-12B polypeptide, and an IL-12A polypeptide; wherein the IL-12A, IL-12B, and IL-1RA polypeptides are operably linked to each other by one or more autoproteolytic cleavage sequences or internal ribosome entry sites.

[0100] In some embodiments, step (a) of the method described herein comprises providing a plurality of srRNA expression constructs, each of which comprises a coding sequence for a variant of PCI. The term "variant" of PCI refers to a polypeptide construct in which there is one or more molecular alterations (e.g., amino acid deletions, substitutions, insertions, duplications, and / or mutations) compared to the amino acid sequence of the original PCI. The term variant also includes frameshift variants and splice variants. In some embodiments, providing in (a) comprises i) obtaining an alphavirus srRNA expression vector in which at least a portion of the coding sequence for an alphavirus structural protein is replaced with the coding sequence for a polypeptide construct of interest (PCI); and ii) generating a plurality of srRNA expression constructs, each of which comprises a coding sequence for a variant of PCI.

[0101] In some embodiments, step (a) of the methods described herein comprises providing a plurality of srRNA expression constructs, each of which comprises a coding sequence for a variant of PCI, wherein providing in (a) comprises: (i) obtaining coding sequences for a plurality of variants of a polypeptide construct of interest (PCI); and (ii) generating a plurality of srRNA expression constructs, each of which comprises the coding sequence of one PCI variant of the plurality of PCI variants from (a) operably inserted into an alphavirus srRNA vector, wherein at least a portion of the coding sequence of an alphavirus structural protein is replaced with the coding sequence of the PCI variant.

[0102] In some embodiments of the methods described herein, a PCI variant of the plurality of PCI variants comprises one or more molecular modifications. The type of molecular modification of the PCI variant may be, for example, one or more of a deletion, a substitution, an insertion, a duplication, a mutation, a frameshift variant, a splice variant, and any combination thereof.

[0103] In some embodiments of the methods described herein, the one or more molecular modifications are organized into multiple modification cassettes. In some embodiments, the multiple modification cassettes are arranged in tandem along the length of the PCI sequence. In some embodiments, the length and amino acid composition of the modification cassettes can be optimized to achieve a desired activity or property of the PCI or PCI variant. In some embodiments, one modification cassette of the multiple modification cassettes comprises a single polypeptide sequence comprising about 1 to about 30 amino acid residues (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid residues, etc.). In some embodiments, one of the multiple modification cassettes contains about 2 to about 50 amino acid residues, for example, about 5 to about 45, about 10 to about 40, about 15 to about 30, about 20 to about 50, about 2 to about 30, about 3 to about 25, about 4 to about 20, about 5 to about 15, about 6 to about 10, about 3 to about 15, about 4 to about 10, about 5 to about 30, about 2 to about 5, about 3 to about 5, or about 4 to about 8 amino acid residues. In some embodiments, one of the multiple modification cassettes contains 31 amino acid residues. In some embodiments, one of the multiple modification cassettes contains 1, 2, 3, 4, 5, or more molecular modifications.

[0104] In some embodiments, the coding sequence of PCI is refactored and / or optimized for desired properties such as increased stability, efficacy, and expression (e.g., translation efficiency), thereby maximizing the effectiveness of biotherapeutic manufacturing, delivery, and administration. For example, in some embodiments, the coding sequence of PCI is optimized to express at a level higher than the expression level of a reference coding sequence, e.g., 20% higher, 30% higher, 40% higher, 50% higher, 60% higher, 70% higher, 80% higher, 90% higher, or 95% higher than the reference coding sequence. In some embodiments, the reference coding sequence is a wild-type, non-optimized sequence. With regard to sequence optimization of a nucleotide sequence, due to the degeneracy of the genetic code, it may be possible to replace at least one base of the protein coding sequence of a gene with a different base without changing the amino acid sequence of the polypeptide produced from the gene. Thus, the nucleic acid construct of the present disclosure may also have any base sequence that has been altered from any polynucleotide sequence disclosed herein by substitution according to the degeneracy of the genetic code. Literature describing codon usage is publicly available and readily available. In some embodiments, polynucleotide sequence variants may be generated for a variety of reasons, such as optimizing expression in a particular host (e.g., changing the codon usage in an alphavirus mRNA to match other organisms, such as humans, non-human primates, hamsters, mice, or monkeys). Thus, in some embodiments, the coding sequence of the PCI is optimized to be expressed at a higher level in a target host cell than the expression level of a reference coding sequence, such as a coding sequence that is not codon-optimized, for example, through the use of codons optimized for expression. In some embodiments, the codon-optimized sequence of the PCI results in an increase in expression level of at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 100% compared to the reference coding sequence that is not codon-optimized.In some embodiments, the codon-optimized sequence of a PCI results in an increase in expression levels of at least 2-fold, at least 3-fold, at least 4-fold, or at least 5-fold compared to a non-codon-optimized reference coding sequence.

[0105] In some embodiments, the coding sequence of PCI is optimized to enhance RNA stability and / or expression. RNA stability is generally related to the "half-life" of RNA. "Half-life" refers to the period required for half of the activity, amount, or number of a molecule to be removed. In the context of the present disclosure, RNA half-life is an indicator of RNA stability. RNA half-life may affect the "expression period" of RNA. Several methods and techniques are known that are useful for evaluating RNA stability, for example, various in silico methods and / or experimental stress tests test the preservation of replicons, such as self-replicating RNAs with different codon usage of PCI, and the effect of said preservation on the effectiveness of srRNA (e.g., testing dsRNA in cells after transfection) and gene expression. Further information on this is available, for example, in Wayment-Steele, H. et al. (2021). Cold Spring Harbor Laboratory (doi.org / 10.1101 / 2020.08.22.262931). Further information on principles, strategies, and methods used to enhance RNA stability is available, for example, in Leppek K. et al., Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics. bioRxiv. (Preprint). Mar 30, 2021. doi: 10.1101 / 2021.03.29.437587.

[0106] In some embodiments, the multiple modified cassettes are operably linked to one another by one or more linkers. In some embodiments, one of the one or more linkers comprises a synthetic compound linker or a peptide linker. In some embodiments, the linker can be a synthetic compound linker, such as a chemical crosslinker. Non-limiting examples of suitable commercially available cross-linkers include N-hydroxysuccinimide (NHS), disuccinimidyl suberate (DSS), bis(sulfosuccinimidyl)suberate (BS3), dithiobis(succinimidyl propionate) (DSP), dithiobis(sulfosuccinimidyl propionate) (DTSSP), ethylene glycol bis(succinimidyl succinate) (EGS), ethylene glycol bis(sulfosuccinimidyl succinate) (sulfoEGS), disuccinimidyl tartrate (DST), disulfosuccinimidyl tartrate (sulfo-DST), bis[2-(succinimidooxycarbonyloxy)ethyl]sulfone (BSOCOES), and bis[2-(sulfosuccinimidooxycarbonyloxy)ethyl]sulfone (sulfo-BSOCOES).

[0107] In some embodiments, the linker may be a peptide linker that connects two adjacent modified cassettes, as described herein. In some embodiments, the length and amino acid composition of the peptide linker sequence may be optimized to alter the orientation, flexibility, and / or proximity of the modified cassettes relative to each other to achieve a desired activity or property of the PCI or PCI variant.

[0108] In some embodiments, the polypeptide linker comprises a single-chain polypeptide sequence comprising about 1 to about 30 amino acid residues (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid residues, etc.). In some embodiments, the linker sequence comprises about 2 to 30, about 3 to 25, about 4 to 20, about 5 to 15, about 6 to 10, about 3 to 15, about 4 to 10, about 5 to 30, about 2 to 5, about 3 to 5, or about 4 to 8 amino acid residues.

[0109] In some embodiments, the length and amino acid composition of the linker polypeptide sequence can be optimized to change the orientation, flexibility, and / or proximity of the modified cassettes relative to each other to achieve a desired activity or property of PCI. In some embodiments, the orientation, flexibility, and / or proximity of the modified cassettes relative to each other can be changed as a "tuning" tool to achieve a tuning effect, such as enhancing or reducing the activity of PCI or PCI variants. In certain embodiments, the linker contains only glycine and / or serine residues (e.g., a glycine-serine linker). Examples of such polypeptide linkers include: Gly, Ser; GlySer; GlyGlySer; SerGlyGly; GlyGlyGlySer; SerGlyGlyGly; GlyGlyGlyGlyGlySer; SerGlyGlyGlyGly; GlyGlyGlyGlyGlyGlyGlySer; SerGlyGlyGlyGlyGly; GlyGlyGlyGlyGlyGlyGlyGlyGly; (GlyGlyGlyGlySer)n, where n is an integer equal to or greater than 1; and (SerGlyGlyGlyGly)n, where n is an integer equal to or greater than 1. In some embodiments, the polypeptide linker is modified such that the amino acid sequence GlySerGly (GSG), which occurs at the junction of a traditional Gly / Ser linker polypeptide repeat, is absent. In some embodiments, the peptide linker comprises an amino acid sequence selected from the group consisting of AAY, EAAAK (SEQ ID NO:1), RVRR (SEQ ID NO:2), GGGGS (SEQ ID NO:3), and GPGPG (SEQ ID NO:4).

[0110] Analysis of PCI levels and / or functionality As described above, the method of the present disclosure includes a process of analyzing the level and / or functionality of PCIs expressed from multiple srRNA expression constructs and identifying one or more candidate PCIs having defined properties (see, e.g., FIG. 1). The analysis of PCI levels and / or functionality can be performed in vitro, in vivo, or ex vivo. In some embodiments, the analysis of PCI levels and / or functionality can include one or more analytical techniques. Examples of suitable analytical techniques include, but are not limited to, immunoblot analysis, fluorescent flow cytometry analysis, enzyme-linked immunosorbent assay analysis, immunogenicity analysis, bioactivity analysis, and efficacy in disease models.

[0111] Generation of a combinatorial collection of delivery systems containing srRNA expression constructs As mentioned above, the method of the present disclosure includes a process of incorporating the srRNA expression construct capable of expressing the candidate PCI identified in (b) into at least one delivery vehicle to create a combinatorial collection of delivery systems. Examples of delivery vehicles suitable for the methods and compositions of the present disclosure include, but are not limited to, physiological buffers, liposomes, lipid-based nanoparticles (LNPs), polymeric nanoparticles, viral replicon particles (VRPs), microspheres, immune stimulating complexes (ISCOMs), and conjugates of bioactive ligands that can facilitate delivery and / or enhance immune responses. These compounds are readily available to those skilled in the art (see, for example, Liposomes: A Practical Approach, RCP New Ed, IRL press (1990)). Adjuvants other than liposomes and the like are also used and are known in the art. Adjuvants may locally confine antigens (e.g., srRNA constructs) to protect them from rapid dispersion or stimulate the host to secrete chemotactic factors for macrophages and other components of the immune system. Those skilled in the art will be able to make appropriate selections based on the following description and the like.

[0112] In some embodiments, the delivery system may comprise one or more of a physiological buffer, a liposome, a lipid-based nanoparticle (LNP), a polymeric nanoparticle, a viral replicon particle (VRP), a microsphere, an immune stimulating complex (ISCOM), a conjugate of a bioactive ligand, or any combination thereof.

[0113] Examples of lipid types suitable for the delivery systems described herein include cationic lipids, ionizable cationic lipids, anionic lipids, neutral lipids, and combinations thereof.

[0114] In some embodiments, the LNPs of the present disclosure may include one or more ionizable lipids. Examples of ionizable lipids suitable for the compositions and methods of the present disclosure include those described in WO 2020 / 252589(A1) and WO 2021 / 000041(A1), and Love KT et al., Proc Natl Acad Sci USA, Feb. 2, 2010 107 (5) 1864-1869, which are incorporated by reference in their entireties.

[0115] Thus, in some embodiments, the LNPs of the present disclosure comprise one or more lipid compounds described in Love KT et al., supra, 2010, such as C16-96, C14-110, and C12-200. In some embodiments, the LNPs comprise an ionizable cationic lipid selected from the group consisting of ALC-0315, C12-200, LN16, MC3, MD1, SM-102, and any combination thereof. In some embodiments, the LNPs of the present disclosure comprise C12-200.

[0116] In some embodiments, the LNPs of the present disclosure comprise one or more cationic lipids. Suitable cationic lipids include, but are not limited to, 98N12-5, C12-200, C14-PEG2000, DLin-KC2-DMA (KC2), DLin-MC3-DMA (MC3), XTC, MD1, and 7C1.

[0117] In some embodiments, the LNPs of the present disclosure include one or more neutral lipids. As described above, neural lipids, also known as "structured lipids" or "helper lipids," can also be incorporated into lipid formulations and lipid particles in some embodiments. Lipid formulations and lipid particles can include one or more structured lipids at about 10-40 mol % of the composition. Suitable structured lipids support the formation of particles during manufacture. Structured lipid refers to any of a number of lipid species that exist in either anionic, uncharged, or neutral zwitterionic form at physiological pH. Exemplary structured lipids include diacylphosphatidylcholine, diacylphosphatidylethanolamine, diacylphosphatidylglycerol, ceramide, sphingomyelin, dihydrosphingomyelin, cephalin, and cerebrosides.

[0118] Examples of structured lipids include distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoyl-phosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (POPE), dioleoyl-phosphatidylethanolamine Zwitterionic lipids such as 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoylphosphatidylethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoylphosphatidylethanolamine (DSPE), 16-O-monomethylPE, 16-O-dimethylPE, 18-1-transPE, 1-stearoyl-2-oleoyl-phosphatidylethanolamine (SOPE), and 1,2-dielideyl-sn-glycero-3-phosphoethanolamine (transDOPE).

[0119] In other embodiments, the structured lipid can be any lipid that is negatively charged at physiological pH.These lipids include phosphatidylglycerols such as dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), palmitoyloleylphosphatidylglycerol (POPG) and cardiolipin; phosphatidylinositol; diacylphosphatidylserine; diacylphosphatidic acid; and other anionic modifying groups attached to neutral lipids; and the like.Other suitable structured lipids include glycolipids (e.g., monosialoganglioside GM1).

[0120] Non-limiting examples of neutral lipids suitable for the compositions and methods of the present disclosure include DPSC, DPPC, POPC, DOPE, and SM. In some embodiments, the LNPs of the present disclosure comprise one or more ionizable lipid compounds described in WO 2020 / 252589(A1) and WO 2021 / 000041(A1), which are incorporated by reference in their entireties.

[0121] In some embodiments, the LNPs of the disclosure comprise at least one lipid selected from the group consisting of C12-200, C14-PEG2000, DOPE, DMG-PEG2000, DSPC, DOTMA, DOSPA, DOTAP, DMRIE, DC-cholesterol, DOTAP-cholesterol, GAP-DMORIE-DPyPE, and GL67A-DOPE-DMPE-polyethylene glycol (PEG).

[0122] In some embodiments, the delivery systems described herein comprise LNPs, and the mass ratio of lipids to nucleic acid in the LNP delivery system is about 100:1 to about 3:1, about 70:1 to 10:1, or 16:1 to 4:1. In some embodiments, the mass ratio of lipids to nucleic acid in the LNP delivery system is about 16:1 to 4:1. In some embodiments, the mass ratio of lipids to nucleic acid in the LNP delivery system is about 20:1. In some embodiments, the mass ratio of lipids to nucleic acid in the LNP delivery system is about 8:1. In some embodiments, the lipid-based nanoparticles (LNPs) have an average diameter of less than about 1000 nm, less than about 500 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, less than about 50 nm, or less than about 25 nm. In some embodiments, the LNPs have an average diameter in the range of about 70 nm to 100 nm. In some embodiments, the LNPs have an average diameter ranging from about 88 nm to about 92 nm, 82 nm to about 86 nm, or about 80 nm to about 95 nm.

[0123] To ensure the integrity of the mixture, a stabilizer can be included in the lipid formulation embodiment. A stabilizer is a type of molecule that disrupts or aids in the formation of hydrophobic-hydrophilic interactions between molecules. Suitable stabilizers include, but are not limited to, polysorbate 80 (also known as Tween 80; 1UPAC name 2-[2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl octadec-9-enoate), Myrj52 (polyoxyethylene(40) stearate), and Brij™ S10 (polyoxyethylene(10) stearyl ether). Polyethylene glycol-linked lipids may be used. Stabilizers may be used alone or in combination with each other.

[0124] In some embodiments, the stabilizer comprises about 0.1-3 mol% of the total lipid mixture. In some embodiments, the stabilizer comprises about 0.5-2.5 mol% of the total lipid mixture. In some embodiments, the stabilizer is present at greater than 2.5 mol%. In some embodiments, the stabilizer is present at 5 mol%. In some embodiments, the stabilizer is present at 10 mol%. In some embodiments, the stabilizer is present at about 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, etc. In other embodiments, the stabilizer is present at about 2.6-10 mol% of the lipid mixture. In other embodiments, the stabilizer is present at greater than 10 mol% in the lipid mixture.

[0125] Steroids may also be included in the lipid composition for certain applications, and lipid particles made therefrom include sterols such as cholesterol and phytosterols.

[0126] In vivo or ex vivo evaluation of pharmacodynamic effects As described above, some embodiments of the disclosed method include a process of analyzing the delivery system for its ability to impart at least one pharmacodynamic effect in a subject and identifying an srRNA expression construct capable of imparting the desired pharmacodynamic effect. In some embodiments, the analysis of the delivery system for its ability to impart at least one pharmacodynamic effect in step (d) is performed in vivo or ex vivo. Examples of pharmacodynamic effects that can be analyzed include immunogenic effects (e.g., effects that induce an immune response in vivo), biomarker responses, therapeutic effects, preventive effects, desirable effects, undesirable effects, side effects, and effects in disease models. In some embodiments, the evaluation of the pharmacodynamic effect includes evaluating the induction of an immune response in vivo (see, e.g., Examples 1-4). In some embodiments, the evaluation of the pharmacodynamic effect includes evaluating the induction of cytokine pathways that can enhance immune responses and prevent angiogenesis and metastasis (see, e.g., Examples 5-7).

[0127] In some embodiments of the methods described herein, the recombinant alphavirus srRNA is from a virus belonging to the genus Alphavirus in the family Togaviridae. In some embodiments, the recombinant alphavirus srRNA is from an alphavirus belonging to the VEEV / EEEV group, or the SFV group, or the SINV group. In some embodiments, the alphavirus is Eastern Equine Encephalitis Virus (EEEV), Venezuelan Equine Encephalitis Virus (VEEV), Everglades Virus (EVEV), Mucambo Virus (MUCV), Pixuna Virus (PIXV), Middleburg Virus (MIDV), Chikungunya Virus (CHIKV), O'Nyong-nyong Virus (ONNV), Ross River Virus (RRV), Barmah Forest Virus (BF), Getah Virus (GET), Sagiyama Virus (SAGV). In some embodiments, the alphavirus is VEEV, EEEV, CHIKV, or SINV. In some embodiments, the alphavirus is VEEV. In some embodiments, the alphavirus is EEEV. In some embodiments, the alphavirus is CHIKV. In some embodiments, the alphavirus is SINV. In some embodiments, the alphavirus is VEEV, EEEV, CHIKV, or SINV. In some embodiments, the alphavirus is VEEV. In some embodiments, the alphavirus is EEEV. In some embodiments, the alphavirus is CHIKV. In some embodiments, the alphavirus is SINV.

[0128] Sequences of suitable wild-type alphaviruses are well known and available from sequence depositories such as the American Type Culture Collection (Rockville, Md.). Representative examples of suitable alphaviruses include Aura (ATCC VR-368), Bebaru virus (ATCC VR-600, ATCC VR-1240), Kabaso (ATCC VR-922), Chikungunya virus (ATCC VR-64, ATCC VR-1241), Eastern equine encephalomyelitis virus (ATCC VR-65, ATCC VR-1242), Fort Morgan (ATCC VR-924), Getah virus (ATCC VR-369, ATCC VR-1243), Kizilagak (ATCC VR-927), Mayaro (ATCC VR-66), Mayaro virus (ATCC VR-1277), Middleburg (ATCC VR-370), Mukambo virus (ATCC VR-580, ATCC VR-1244), Nudum (ATCC VR-370), and the like. VR-371), Pixuna virus (ATCC VR-372, ATCC VR-1245), Ross River virus (ATCC VR-373, ATCC VR-1246), Semliki Forest virus (ATCC VR-67, ATCC VR-1247), Sindbis virus (ATCC VR-68, ATCC VR-1248), Tonate (ATCC VR-925), Triniti (ATCC VR-469), Una (ATCC VR-374), Venezuelan equine encephalomyelitis (ATCC VR-69, ATCC VR-923, ATCC VR-1250 ATCC VR-1249, ATCC VR-532), Western equine encephalomyelitis (ATCC VR-70, ATCC VR-1251, ATCC VR-622, ATCC VR-1252), Wataroa (ATCC VR-926), and Y-62-33 (ATCC VR-375).

[0129] In some embodiments, the alphavirus is chikungunya virus (CHIKV). Non-limiting examples of CHIKV strains suitable for the compositions and methods of the present disclosure include CHIKV S27, CHIKV LR2006-OPY-1, CHIKV YO123223, CHIKV DRDE, CHIKV 37997, CHIKV 99653, CHIKV Ag41855, and Nagpur (India) 653496. Both virulent and avirulent CHIKV strains are suitable. Further examples of CHIKV strains suitable for the compositions and methods of the present disclosure include, but are not limited to, those described in Afreen et al. Microbiol. Immunol. 2014, 58:688-696, Lanciotti and Lambert ASTMH 2016, 94(4):800-803, and Langsjoen et al. mBio. 2018, 9(2):e02449-17. In some embodiments, the modified CHIKV genome or replicon, such as a self-replicating RNA, is derived from CHIKV strain S27. In some embodiments, the modified CHIKV genome or srRNA is derived from CHIKV strain DRDE. In some embodiments, the modified CHIKV genome or srRNA is derived from CHIKV strain DRDE-06. In some embodiments, the modified CHIKV genome or srRNA is derived from CHIKV strain DRDE-07.

[0130] In some embodiments, the alphavirus is Eastern Equine Encephalitis Virus (EEEV) or Madariaga Virus (MADV). Non-limiting examples of EEEV and MADV strains suitable for the compositions and methods of the present disclosure include EEEV 792138, 783372, BeAn5122, BeAr300851, BeAr436087, C-49, FL91-4679, FL93-939, GML903836, MP-9, PE6, and V105-00210. Both virulent and avirulent EEEV strains are suitable. Additional suitable EEEV strains include, but are not limited to, those listed on the Virus Pathogen Resource website (ViPR; available at www.viprbrc.org / brc / vipr_genome_search.spg?method=SubmitForm&blockId=868&decorator=toga). In some embodiments, the modified EEEV genome or replicon, e.g., a self-replicating RNA, is derived from EEEV strain FL93-939. Additional suitable MADV strains include, but are not limited to, those described in Arrigo et al., J. Virology, Jan 2010, 1014-1025, which are incorporated by reference in their entireties. In some embodiments, the modified MADV genome or replicon, e.g., a self-replicating RNA, is derived from MADV strain BeAr300851.

[0131] In some embodiments, the alphavirus is Sindbis virus (SINV). In some embodiments, the modified genome or replicon, e.g., self-replicating RNA, is of a SINV strain. Non-limiting examples of SINV strains suitable for the compositions and methods of the present disclosure include SINV strains AR339, AR86, and Girdwood. Examples of SINV strains suitable for the compositions and methods of the present disclosure include, but are not limited to, those described in Sammels et al. J. Gen. Virol. 1999, 80(3):739-748; Lundstrom and Pfeffer Vector Borne Zoonotic Dis. 2010, 10(9):889-907; Sigei et al. Arch. of Virol. 2018, 163:2465-2469; and Ling et al. J. Virol. 2019, 93:e00620-19. Further suitable SINV strains include, but are not limited to, those listed on the Virus Pathogen Resource website (ViPR). Both virulent and avirulent SINV strains are suitable. In some embodiments, the modified genome or srRNA is from SINV strain Girdwood. In some embodiments, the modified genome or srRNA is from SINV strain AR86. In some embodiments, the modified SINV genome or srRNA is from SINV strain Girdwood. In some embodiments, the modified SINV genome or srRNA is from SINV strain AR86. In some embodiments, at least one heterologous nsP or portion thereof of the modified genome or srRNA is from SINV strain AR86. In some embodiments, at least one heterologous nsP or portion thereof is nsP1, nsP3, nsP4, or any portion thereof, or any combination of the foregoing. In some embodiments, the modified genome or srRNA is from SINV strain AR86.

[0132] In some embodiments, the alphavirus is Western Equine Encephalitis Virus (WEEV). Non-limiting examples of WEEV strains suitable for the compositions and methods of the present disclosure include WEEV California, McMillan, IMP181, Imperial, Imperial181, IMPR441, 71V-1658, AG80-646, BFS932, COA592, EP-6, E1416, BFS1703, BFS2005, BSF3060, BSF09997, CHLV53, KERN5547, 85452NM, Montana-64, S8-122, and TBT-235. Further examples of WEEV strains suitable for the compositions and methods of the present disclosure include 5614, 93A27, 93A30, 93A38, 93A79, B628(Cl 15), CBA87, CNTR34, CO921356, Fleming, Lake43, PV012357A, PV02808A, PV72102, R02PV001807A, R02PV002957B, R02PV003422B, R05PV003422B, R0PV003814A, and R0PV00384A. Both virulent and avirulent WEEV strains are suitable. Additional suitable WEEV strains include, but are not limited to, those described in Berggren NA et al., J. Virol. 88(16): 9260-9267, Aug 2014, and the Virus Pathogen Resource website (ViPR). In some embodiments, the modified WEEV genome or srRNA is derived from WEEV strain Imperia.

[0133] In some embodiments of the methods described herein, the srRNA expression vector is identified as having immune-inducing activity suitable for prophylactic and / or therapeutic use. In some embodiments, the srRNA expression vector is identified as having immune-inducing activity suitable for prophylactic use. In some embodiments, the srRNA expression vector is identified as having immune-inducing activity suitable for therapeutic use.

[0134] Compositions of the Disclosure nucleic acid construct As described in more detail below, one aspect of the disclosure relates to a nucleic acid construct comprising a nucleic acid sequence encoding an srRNA construct described herein. In some embodiments, the sequence encoding the srRNA construct can be operably linked, such as by being placed under the control of elements required for expression, such as a promoter sequence, thereby allowing expression of the srRNA construct in a host cell, in a subject, or in an ex vivo cell-free expression system.

[0135] The terms "nucleic acid molecule" and "polynucleotide" are used interchangeably herein and refer to both RNA and DNA molecules, including cDNA, genomic DNA, synthetic DNA, and DNA or RNA molecules, including nucleic acid analogs. Nucleic acid molecules can be double-stranded or single-stranded (e.g., sense or antisense). Nucleic acid molecules may contain unusual or modified nucleotides. As used herein, the terms "polynucleotide sequence" and "nucleic acid sequence" refer interchangeably to the sequence of a polynucleotide molecule. The sequences of polynucleotides and polypeptides disclosed herein are shown using standard letter abbreviations for nucleotide bases and amino acids, as set forth in WIPO Standard ST.25 (1998), Appendix 2, Tables 1-6 (37 CFR §1.82, which is incorporated by reference).

[0136] The nucleic acid molecules of the present disclosure may be any length of nucleic acid molecule, for example, the length of the nucleic acid molecule is typically between about 2 kb and 50 kb, for example, between about 5 kb and about 40 kb, between about 5 kb and about 30 kb, between about 5 kb and about 20 kb, between about 10 kb and about 50 kb, between about 15 kb and 30 kb, between about 20 kb and about 50 kb, between about 20 kb and about 40 kb, between about 5 kb and about 25 kb, or between about 30 kb and about 50 kb. In some embodiments, the length of the nucleic acid molecule is at least 6 kb. In some embodiments, the nucleic acid molecule is between about 6 kb and about 20 kb. In some embodiments, the nucleic acid constructs (e.g., vectors or srRNA constructs) of the present disclosure typically have a length of at least about 2 kb. For example, a nucleic acid construct (e.g., a vector or srRNA) can have a length of at least about 2 kb, at least about 3 kb, at least about 4 kb, at least about 5 kb, at least about 6 kb, at least about 7 kb, at least about 8 kb, at least about 9 kb, at least about 10 kb, at least about 11 kb, at least about 12 kb, or more than 12 kb. In some embodiments, the nucleic acid construct (e.g., a vector or srRNA) may be from about 4 kb to about 20 kb, from about 4 kb to about 18 kb, from about 5 kb to about 16 kb, from about 6 kb to about 14 kb, from about 7 kb to about 12 kb, from about 8 kb to about 16 kb, from about 9 kb to about 14 kb, from about 10 kb to about 18 kb, from about 11 kb to about 16 kb, from about 5 kb to about 18 kb, from about 6 kb to about 20 kb, from about 5 kb to about 10 kb, from about 5 kb to about 8 kb, from about 5 kb to about 7 kb, It may have a length of 5 kb to about 6 kb, about 6 kb to about 12 kb, about 6 kb to about 11 kb, about 6 kb to about 10 kb, about 6 kb to about 9 kb, about 6 kb to about 8 kb, about 6 kb to about 7 kb, about 7 kb to about 11 kb, about 7 kb to about 10 kb, about 7 kb to about 9 kb, about 7 kb to about 8 kb, about 8 kb to about 11 kb, about 8 kb to about 10 kb, about 8 kb to about 9 kb, about 9 kb to about 11 kb, about 9 kb to about 10 kb, or about 10 kb to about 11 kb. In some embodiments, the nucleic acid construct (e.g., vector or srRNA) may have a length of about 6 kb to about 14 kb. In some embodiments, the nucleic acid construct (e.g., vector or srRNA) may have a length of about 6 kb to about 16 kb.

[0137] In some embodiments, the nucleic acid sequence encoding the srRNA construct is incorporated into an expression cassette or expression vector. It will be understood that an expression cassette generally comprises a construct of genetic material that includes a coding sequence for srRNA and sufficient regulatory information to direct proper transcription and / or translation of the coding sequence in a recipient cell in vivo and / or ex vivo. Typically, the expression cassette may be inserted into a vector for targeting to a desired host cell and / or subject or individual. In some embodiments, the term expression cassette may be used interchangeably with the term "expression construct." Thus, in some embodiments, an expression cassette of the present disclosure comprises a coding sequence for the srRNA disclosed herein, which sequence is operably linked to expression control elements such as a promoter, and optionally to any or a combination of other nucleic acid sequences that affect the transcription or translation of the coding sequence.

[0138] In some embodiments, the nucleotide sequence is incorporated into an expression vector. The term "vector" generally refers to a recombinant polynucleotide construct designed for transfer between host cells, and those skilled in the art will understand that it may be used for purposes of transformation, e.g., introducing heterologous DNA into a host cell. Thus, in some embodiments, a vector may be a replicon (e.g., srRNA), such as a plasmid, phage, or cosmid, into which another DNA segment may be inserted to effect replication of the inserted segment. In some embodiments, an expression vector may be an integrating vector.

[0139] Molecular techniques and methods by which the nucleic acid constructs of the present disclosure can be constructed and characterized are described in further detail in the Examples section of this application.

[0140] In some embodiments, the nucleic acid molecule is a recombinant nucleic acid molecule. As mentioned above, the term recombinant nucleic acid molecule refers to a nucleic acid molecule (e.g., DNA or RNA) that has been manipulated by human beings or that is indirectly generated as a result of human manipulation. As a non-limiting example, cDNA is a recombinant DNA molecule, as is any nucleic acid molecule produced by an in vitro polymerase reaction, any nucleic acid molecule that is linked with a linker, or any nucleic acid molecule that is incorporated into a vector, such as a cloning vector or an expression vector. As non-limiting examples, recombinant nucleic acid molecules are: 1) synthesized or modified in vitro, for example, using chemical or enzymatic techniques (e.g., by the use of chemical nucleic acid synthesis or by the use of enzymes for replication, polymerization, exonucleolytic digestion, endonucleolytic digestion, ligation, reverse transcription, transcription, base modification (e.g., methylation), or recombination (e.g., homologous recombination and site-specific recombination) of nucleic acid molecules; 2) contain linked nucleotide sequences that are not linked in nature; 3) have been engineered using molecular cloning techniques to lack one or more nucleotides relative to the naturally occurring nucleotide sequence; and / or 4) have been engineered using molecular cloning techniques to have one or more sequence changes or rearrangements relative to the naturally occurring nucleotide sequence.

[0141] In some embodiments, the nucleic acid molecules disclosed herein are produced using recombinant DNA technology (e.g., polymerase chain reaction (PCR) amplification and cloning, etc.) or chemical synthesis. The nucleic acid molecules disclosed herein include naturally occurring nucleic acid molecules and their homologues, including, but not limited to, naturally occurring allelic variants and modified nucleic acid molecules in which one or more nucleotide residues have been inserted, deleted, and / or substituted in a manner that provides desirable properties in providing the biological activity described herein.

[0142] Those skilled in the art will appreciate that nucleic acid molecules, such as variants of naturally occurring nucleic acid sequences, can be generated using a number of methods known to those skilled in the art (see, for example, Sambrook et al., In: Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Press, Cold Spring Harbor, NY (1989)). The sequence of a nucleic acid molecule can be modified relative to the native sequence from which it is derived using a variety of techniques, including, but not limited to, classical mutagenesis and recombinant DNA techniques, such as, but not limited to, site-directed mutagenesis, chemical treatment of a nucleic acid molecule to induce mutations, restriction enzyme cleavage of nucleic acid fragments, ligation of nucleic acid fragments, PCR amplification and / or mutagenesis of selected regions of a nucleic acid sequence, and recombinational cloning; chemical synthesis, such as chemical synthesis of a mixture of oligonucleotides, and ligation of mixture groups to "build" a mixture of nucleic acid molecules; and combinations thereof. Selection of a homologue of a nucleic acid molecule from a mixture of modified nucleic acid molecules is possible by screening the function of the protein or replicon, e.g. a self-replicating RNA, encoded by the nucleic acid molecule and / or by hybridization with a wild-type gene or fragment thereof, or by PCR using primers homologous to a target or wild-type nucleic acid molecule or sequence.

[0143] Recombinant cells As described in more detail below, one aspect of the disclosure relates to recombinant cells engineered to contain a nucleic acid construct described herein and / or to contain (e.g., express) a srRNA construct described herein. In some embodiments, the nucleic acid construct and / or srRNA construct of the disclosure can be introduced into a host cell to produce a recombinant cell containing the nucleic acid construct and / or srRNA construct. Thus, prokaryotic or eukaryotic cells that contain the srRNA construct described herein and / or contain a nucleic acid construct encoding the srRNA construct described herein are also a feature of the disclosure. Introduction of the srRNA construct and nucleic acid construct of the disclosure into cells can be accomplished by methods known to those of skill in the art, including viral infection, transfection, conjugation, protoplast fusion, lipofection, electroporation, nucleofection, calcium phosphate precipitation, polyethyleneimine (PEI)-mediated transfection, DEAE-dextran-mediated transfection, liposome-mediated transfection, particle gun technology, direct microinjection, nanoparticle-mediated nucleic acid delivery, and the like.

[0144] Thus, some embodiments of the present disclosure relate to recombinant cells, including recombinant eukaryotic cells such as insect or animal cells, that contain the srRNA constructs and / or nucleic acid constructs described herein. In some embodiments, the recombinant cell contains a nucleic acid construct, which may be stably integrated into the host genome, replicated as an episome, or present in the recombinant host cell as a minicircle expression vector for stable or transient expression. Thus, in some embodiments of the present disclosure, the nucleic acid construct is maintained and replicated in the recombinant host cell as an episomal unit. In some embodiments, the nucleic acid construct is stably integrated into the genome of the recombinant cell. Stable integration can be achieved by using classical random genome recombination techniques, or by using more precise genome editing techniques such as guide RNA-guided CRISPR / Cas9 or TALEN genome editing. In some embodiments, the nucleic acid construct is present in the recombinant host cell as a minicircle expression vector for stable or transient expression.

[0145] A host cell may be an untransformed cell or a cell that has already been transfected with at least one nucleic acid molecule. Thus, in some embodiments, a host cell may be genetically engineered (e.g., transduced, transformed, or transfected) with at least one nucleic acid molecule.

[0146] Suitable host cells for cloning or expressing a polypeptide of interest as described herein include prokaryotic or eukaryotic cells as described herein. Thus, in some embodiments, a recombinant cell of the present disclosure is a prokaryotic cell, such as the bacterium E. coli, or a eukaryotic cell, such as an insect cell (e.g., a mosquito cell or an Sf21 cell) or a mammalian cell (e.g., a COS cell, an NIH 3T3 cell, or a HeLa cell). In some embodiments, the cell is an in vivo cell, e.g., a recombinant cell in a living organism, e.g., a transgenic cell of a subject. In some embodiments, the subject is a vertebrate or an invertebrate. In some embodiments, the subject is an insect. In some embodiments, the subject is a mammalian subject. In some embodiments, the mammalian subject is a human subject. In some embodiments, the cell is an ex vivo cell, e.g., one that has been removed as an individual cell or as part of an organ or tissue from a living organism or organism for therapy or treatment, and then returned to the living organism or organism. In some embodiments, the cell is an in vitro cell, e.g., a cell obtained from a repository.

[0147] In some embodiments of the present disclosure, the recombinant cell of the present disclosure is a eukaryotic cell. In some embodiments, the recombinant cell is an animal cell. In some embodiments, the animal cell is a vertebrate cell or an invertebrate cell. In some embodiments, the recombinant animal cell is a mammalian cell. In some embodiments, non-limiting examples of recombinant cells of the disclosure include SV40 transformed monkey kidney CV1 cells (such as COS-7), human embryonic kidney cells (such as HEK 293 or HEK 293 cells), baby hamster kidney cells (BHK), mouse Sertoli cells (such as TM4 cells), monkey kidney cells (CV1), human cervical carcinoma cells (such as HeLa), canine kidney cells (such as MDCK), buffalo rat hepatocytes (such as BRL 3A), human lung cells (such as W138), human hepatocytes (such as Hep G2), mouse breast carcinoma (such as MMT 060562), TRI cells, FS4 cells, Chinese hamster ovary cells (CHO cells), African green monkey kidney cells (such as Vero cells), human A549 cells, human cervical cells, human CHME5 cells, human PER.C6 cells, NS0 mouse myeloma cells, human laryngeal epidermoid cells, human ovarian cancer cells (HUVECs), ... larynx cells, human fibroblasts, human HUH-7 cells, human MRC-5 cells, human muscle cells, human endothelial cells, human astrocytes, human macrophage cells, human RAW 264.7 cells, mouse 3T3 cells, mouse L929 cells, mouse connective tissue cells, mouse muscle cells, and rabbit kidney cells.

[0148] In some embodiments, the recombinant cells are selected from the group consisting of African green monkey kidney cells (Vero cells), baby hamster kidney cells (BHK cells), Chinese hamster ovary cells (CHO cells), human A549 cells, human cervical cells, human CHME5 cells, human laryngeal epidermoid cells, human fibroblast cells, human HEK-293 cells, human HeLa cells, human HepG2 cells, human HUH-7 cells, human MRC-5 cells, human muscle cells, mouse 3T3 cells, mouse connective tissue cells, mouse muscle cells, and rabbit kidney cells. In some embodiments, the recombinant cells are derived from the above cells (i.e., derived cells of the original cells described herein), including, for example, clonal expansion of the original cells, engineered versions of the original cells, or reclassification of the original cells after many passages or passage through other hosts.

[0149] In some embodiments of the present disclosure, the recombinant cell is an insect cell, for example, a cell of an insect cell line. In some embodiments, the insect cell is an Sf21 cell. Additional suitable insect cell lines include, but are not limited to, cell lines established from the insect orders Diptera, Lepidoptera, and Hemiptera, which may be from various tissue sources. In some embodiments, the recombinant cell of the present disclosure is a cell of a lepidopteran insect cell line. Over the past several decades, the number of available lepidopteran insect cell lines has increased by about 50 per decade. Further information regarding available lepidopteran insect cell lines can be found, for example, in Lynn DE, Available lepidopteran insect cell lines. Methods Mol. Biol. 2007;388:117-38, which is incorporated herein by reference. In some embodiments, the recombinant cell is a mosquito cell, and exemplary mosquito cells include cells of mosquito species within the genera Anopheles (An.), Culex (Cx.), and Aedes (Stegomyia) (Ae.). Exemplary mosquito cell lines suitable for the compositions and methods described herein include cell lines from the following mosquito species: Aedes aegypti, Aedes albopictus, Aedes pseudoscutellaris, Aedes triseriatus, Aedes vexans, Anopheles gambiae, Anopheles stephensi, Anopheles albimanus, Culex quinquefasciatus, Culex theileri, Culex tritaeniorhynchus, Culex bitaeniorhynchus, and Toxorhynchites amboinensis. Suitable mosquito cell lines include, but are not limited to, CCL-125, Aag-2, RML-12, C6 / 26, C6 / 36, C7-10, AP-61, At GRIP-1, At GRIP-2, UM-AVE1, Mos.55, Sua1B, 4a-3B, Mos.43, MSQ43, and LSB-AA695BB. In some embodiments, the mosquito cell is a cell of the C6 / 26 cell line.

[0150] cell culture In another aspect, provided herein is a cell culture comprising at least one recombinant cell disclosed herein and a medium. Typically, the medium may be any suitable medium for culturing the cells described herein. Techniques for transforming the wide variety of host cells and species described above are known in the art and described in the technical and scientific literature. Thus, cell cultures comprising at least one recombinant cell disclosed herein are also within the scope of this application. Methods and systems suitable for generating and maintaining cell cultures are known in the art.

[0151] Transgenic animals In another aspect, a transgenic animal is provided that includes a nucleic acid (e.g., a vector or srRNA molecule) encoding the srRNA construct described herein. In some embodiments, the transgenic animal is a vertebrate or invertebrate animal. In some embodiments, the transgenic animal is a mammal. In some embodiments, the transgenic animal is a non-human mammal. In general, the transgenic animal of the present disclosure can be any non-human animal known in the art. In some embodiments, the non-human animal of the present disclosure is a non-human primate. Other animal species suitable for the compositions and methods of the present disclosure include animals that are (i) suitable for gene transfer and (ii) capable of rearranging immunoglobulin gene segments to generate an antibody response. Examples of such species include, but are not limited to, mice, rats, hamsters, rabbits, chickens, goats, pigs, sheep, and cows. Further examples of non-human animals suitable for the compositions and methods of the present disclosure include, but are not limited to, laboratory animals (such as mice, rats, hamsters, gerbils, and guinea pigs), farm animals (such as horses, cows, pigs, sheep, goats, ducks, geese, and chickens), domesticated animals and pets (such as cats and dogs), non-human primates (such as apes, chimpanzees, orangutans, and monkeys), fish, amphibians (such as frogs and salamanders), reptiles (such as snakes and lizards), and other animals (such as foxes, weasels, rabbits, minks, beavers, ermines, otters, sables, seals, coyotes, chinchillas, deer, muskrats, and possums).

[0152] In some embodiments, the transgenic animal is an insect. In some embodiments, the insect is a mosquito. In some embodiments, the transgenic animal of the present disclosure is a chimeric transgenic animal. In some embodiments, the transgenic animal of the present disclosure is a transgenic animal having germ cells and somatic cells that include one or more (e.g., one or more, two or more, three or more, four or more, etc.) nucleic acid constructs of the present disclosure. In some embodiments, the one or more nucleic acid constructs are stably integrated into the genome of the transgenic animal. In some embodiments, the genome of the transgenic animal of the present disclosure may include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more copies of one or more nucleic acid constructs of the present disclosure.

[0153] Approaches and methods for producing transgenic non-human animals are known in the art. Exemplary methods include pronuclear microinjection, DNA microinjection, introduction of DNA into early embryos via lentiviral vectors, sperm-mediated gene transfer, adenovirus-mediated introduction of DNA into animal sperm (such as in pigs), retroviral vectors (such as in birds), and somatic cell nuclear transfer (such as in goats). A review of the prior art for producing transgenic livestock is given in Niemann, H. et al. (2005) Rev. Sci. Tech. 24:285-298. In some embodiments, the transgenic non-human host animals of the present disclosure are produced using standard methods known in the art for introducing foreign nucleic acid into the genome of a non-human animal. In some embodiments, the transgenic animals of the present disclosure can be generated by using classical random genome recombination techniques, or by using more precise techniques such as guide RNA-guided CRISPR / Cas genome editing, DNA-guided endonuclease genome editing using NgAgo (Natronobacterium gregoryi argonaute), or TALEN genome editing (transcription activator-like effector nuclease). In some embodiments, the transgenic animals of the present disclosure can be generated using transgenic microinjection techniques and do not require the use of homologous recombination techniques, which may make them easier to prepare and select than approaches using homologous recombination. In some embodiments, the transgenic animals produce the proteins of interest described herein.

[0154] Pharmaceutical Compositions The srRNA constructs, nucleic acid constructs, and recombinant cells of the present disclosure can be incorporated into compositions, such as pharmaceutical compositions. Such compositions typically include one or more of the srRNA constructs, nucleic acid constructs, and recombinant cells described and provided herein, and a pharma- ceutically acceptable excipient, such as a carrier. Thus, in one aspect of the present disclosure, provided herein is a pharmaceutical composition comprising a therapeutically acceptable excipient and one or more of the following: (1) an srRNA construct disclosed herein, (2) a nucleic acid disclosed herein, (3) a recombinant cell disclosed herein. In some embodiments, provided herein is a composition comprising an srRNA construct disclosed herein and a pharma- ceutically acceptable excipient. In some embodiments, provided herein is a composition comprising a nucleic acid construct disclosed herein and a pharma- ceutically acceptable excipient. In some embodiments, provided herein is a composition comprising a recombinant cell disclosed herein and a pharma- ceutically acceptable excipient.

[0155] Non-limiting preferred embodiments of the pharmaceutical composition described herein may include one or more of the following features. The srRNA construct of the present disclosure can be used in naked form or formulated with a delivery vehicle. For example, the route can be used in free form or inserted into a nucleic acid such as a vector. For example, as described in more detail below, the srRNA construct described herein can be used as a vaccine.

[0156] In some embodiments, the compositions of the present disclosure are formulated for the prevention, treatment, or management of a condition, such as an immune disorder or a microbial infection. For example, the compositions of the present disclosure can be formulated as a prophylactic composition, a therapeutic composition, or a pharmaceutical composition, or a mixture thereof, including a pharmaceutically acceptable excipient.

[0157] In some embodiments, the compositions of the present disclosure are formulated for use as a vaccine. In some embodiments, the compositions of the present disclosure are formulated for use as an adjuvant. In some embodiments, the compositions of the present disclosure are formulated for use as an immunogenic composition. In some embodiments, the compositions of the present disclosure are formulated for use as a biotherapeutic.

[0158] For use in the pharmaceutical compositions of the present disclosure, the srRNA constructs, nucleic acids, or recombinant cells described herein can be formulated in or with a delivery vehicle. Examples of delivery vehicles suitable for the compositions and methods of the present disclosure include, but are not limited to, liposomes (e.g., neutral or anionic liposomes), microspheres, immune stimulating complexes (ISCOMS), lipid-based nanoparticles (LNPs), polymeric nanoparticles, viral replicon particles (VRPs), or conjugation with bioactive ligands that can facilitate delivery and / or enhance immune responses. These compounds are readily available to those skilled in the art (see, for example, Liposomes: A Practical Approach, RCP New Ed, IRL press (1990)). Adjuvants other than liposomes and the like are also used and are known in the art. Adjuvants may locally confine antigens (e.g., srRNA constructs) to protect them from rapid dispersion, or may include substances that stimulate the host to secrete chemotactic factors for macrophages and other components of the immune system. Those skilled in the art will be able to make appropriate selections based on the following description and the like.

[0159] Thus, in some embodiments, compositions of the present disclosure may comprise one or more of a physiological buffer, a liposome, a lipid-based nanoparticle (LNP), a polymeric nanoparticle, a viral replicon particle (VRP), a microsphere, an immune stimulating complex (ISCOM), a conjugate of a biologically active ligand, or any combination thereof.

[0160] In some embodiments, the srRNA constructs and nucleic acid constructs of the present disclosure can be delivered to cells or subjects by lipid-based nanoparticles (LNPs). LNPs are generally less immunogenic than viral particles. Many people have pre-existing immunity to viral particles, but not to LNPs. Furthermore, the adaptive immune response to LNPs is unlikely to occur, allowing repeated administration of LNPs.

[0161] Lipids suitable for the compositions and methods described herein can be cationic lipids, ionizable cationic lipids, anionic lipids, or neutral lipids.

[0162] In some embodiments, the LNPs of the present disclosure can include one or more ionizable lipids. The term "ionizable lipid" as used herein refers to lipids that become cationic or ionizable (protonated) when the pH is lower than the pKa of the lipid's ionizable group, but are more neutral at higher pH values. At pH values ​​below the pKa, the lipids can bind to negatively charged nucleic acids (e.g., oligonucleotides). The term "ionizable lipid" as used herein includes lipids that become positively charged as the pH decreases from physiological pH, and any of the many lipid species that carry a net positive charge at a selective pH, such as physiological pH. Lipids that remain cationic, such as DOTMA, have been shown to be too toxic for clinical use. Ionizable lipids can be present in lipid formulations according to other embodiments, preferably in a proportion of about 30 to about 70 mol % in some embodiments, about 30 mol % in other embodiments, about 40 mol % in other embodiments, about 45 mol % in other embodiments, about 47.5 mol % in other embodiments, about 50 mol % in still other embodiments, and about 60 mol % in still other embodiments ("mol %" refers to the percentage of the total number of moles of a particular component). In this paragraph, "about" refers to a range of 5 mol % above and below. DODMA, i.e., 1,2-dioleyloxy-3-dimethylaminopropane, is an ionizable lipid, as is DLin-MC3-DMA, i.e., 0-(Z,Z,Z,Z-heptatriaconta-6,9,26,29-tetraen-19-yl)-4-(N,N-dimethylamino) ("MC3").

[0163] Examples of ionizable lipids suitable for the compositions and methods of the present disclosure include those described in WO 2020 / 252589(A1) and 2021 / 000041(A1), U.S. Patent Nos. 8,450,298 and 10,844,028, and Love KT et al., Proc Natl Acad Sci USA, Feb. 2, 2010 107 (5) 1864-1869, all of which are incorporated by reference in their entireties. Thus, in some embodiments, the LNPs of the present disclosure comprise one or more lipid compounds described in Love KT et al. (2010, supra), such as C16-96, C14-110, and C12-200. In some embodiments, the LNPs comprise an ionizable cationic lipid selected from the group consisting of ALC-0315, C12-200, LN16, MC3, MD1, SM-102, and any combination thereof. In some embodiments, the LNPs of the present disclosure comprise a C12-200 lipid. The structure of the C12-200 lipid is known in the art and described, for example, in U.S. Pat. Nos. 8,450,298 and 10,844,028, which are incorporated herein by reference in their entireties. In some embodiments, the C12-200 is combined with cholesterol, C14-PEG2000, and DOPE. In some embodiments, the C12-200 is combined with DSPC and DMG-PEG2000.

[0164] In some embodiments, the LNPs of the present disclosure comprise one or more cationic lipids. Several different ionizable cationic lipids have been developed for use in LNPs. Suitable cationic lipids include, but are not limited to, 98N12-5, C12-200, C14-PEG2000, DLin-KC2-DMA (KC2), DLin-MC3-DMA (MC3), XTC, MD1, and 7C1. In one type of LNP, a GalNAc moiety is added to the outside of the LNP and serves as a ligand for uptake into the liver via the asialoglycoprotein receptor. Any of these cationic lipids can be used to formulate LNPs for delivery of the srRNA constructs and nucleic acid constructs of the present disclosure.

[0165] In some embodiments, the LNPs of the present disclosure comprise one or more neutral lipids. Non-limiting examples of neutral lipids suitable for the compositions and methods of the present disclosure include DPSC, DPPC, POPC, DOPE, and SM. In some embodiments, the LNPs of the present disclosure comprise one or more ionizable lipid compounds described in WO 2020 / 252589(A1) and WO 2021 / 000041(A1).

[0166] Many other lipids or combinations of lipids known in the art can be used to produce LNPs. Non-limiting examples of lipids suitable for producing LNPs include DOTMA, DOSPA, DOTAP, DMRIE, DC-cholesterol, DOTAP-cholesterol, GAP-DMORIE-DPyPE, and GL67A-DOPE-DMPE-polyethylene glycol (PEG). Further non-limiting examples of cationic lipids include 98N12-5, C12-200, C14-PEG2000, DLin-KC2-DMA (KC2), DLin-MC3-DMA (MC3), XTC, MD1, 7C1, and any combination thereof. Further non-limiting examples of neutral lipids include DPSC, DPPC, POPC, DOPE, and SM. Non-limiting examples of PEG-modified lipids include PEG-DMG, PEG-CerC14, and PEG-CerC20.

[0167] In some embodiments, the weight ratio of lipid to nucleic acid in the LNP delivery system is about 100:1 to about 3:1, about 70:1 to 10:1, or 16:1 to 4:1. In some embodiments, the weight ratio of lipid to nucleic acid in the LNP delivery system is about 16:1 to 4:1. In some embodiments, the weight ratio of lipid to nucleic acid in the LNP delivery system is about 20:1. In some embodiments, the weight ratio of lipid to nucleic acid in the LNP delivery system is about 8:1. In some embodiments, the lipid-based nanoparticles have an average diameter of less than about 1000 nm, less than about 500 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, less than about 50 nm, or less than about 25 nm. In some embodiments, the LNPs have an average diameter in the range of about 70 nm to 100 nm. In some embodiments, the LNPs have an average diameter ranging from about 88 nm to about 92 nm, 82 nm to about 86 nm, or about 80 nm to about 95 nm.

[0168] In some embodiments, the composition of the present disclosure is formulated into polymeric nanoparticles. In some embodiments, the composition is an immunogenic composition, for example, a composition that can stimulate an immune response in a subject. In some embodiments, the immunogenic composition is formulated as a vaccine. In some embodiments, the pharmaceutical composition is formulated as an adjuvant.

[0169] In some embodiments, the immunogenic composition is substantially non-immunogenic to a subject, e.g., a composition that stimulates minimally an immune response in a subject. In some embodiments, the non-immunogenic or low-immunogenic composition is formulated as a biotherapeutic. In some embodiments, the pharmaceutical composition is formulated for one or more of intranasal, transdermal, intraperitoneal, intramuscular, intratracheal, intranodal, intratumoral, intraarticular, intravenous, subcutaneous, intravaginal, intraocular, rectal, and oral administration.

[0170] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. Carriers suitable for intravenous administration include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ), or phosphate buffered saline (PBS). In these cases, the composition should be sterile and fluid to the extent that easy syringeability exists. The composition can be stable under the conditions of manufacture and storage and preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium, including water, ethanol, polyol (e.g., glycerol, propylene glycol, liquid polyethylene glycol, and the like), and suitable mixtures thereof. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants such as sodium dodecyl sulfate. Prevention of microbial action can be achieved by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be common to include isotonic agents such as sugars; polyalcohols such as mannitol and sorbitol; and / or sodium chloride in the composition. Prolonged absorption of the injectable composition can be achieved by including an agent that delays absorption in the composition, such as aluminum monostearate and gelatin.

[0171] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and the required other ingredients from those enumerated above.

[0172] In some embodiments, the pharmaceutical compositions of the present disclosure are formulated for inhalation, such as as an aerosol, spray, mist, liquid, or powder. For administration by inhalation, either the form of a dry powder or an aerosol formulation may be used, which is inhaled by a subject (such as a patient) by use of an inhalation device, such as a microspray, a pressurized metered dose inhaler, or a nebulizer.

[0173] In some embodiments, the composition is formulated for one or more of intranasal, transdermal, intramuscular, intranodal, intratumoral, intraarticular, intravenous, intraperitoneal, intratracheal, oral, intravaginal, intraocular, intrarectal, or intracranial administration. In some embodiments, the administered composition results in increased production of interferon in the subject.

[0174] kit Also provided herein are various kits for carrying out the methods described herein. In particular, some embodiments of the present disclosure provide kits for inducing an immune response in a subject. Some other embodiments relate to kits for preventing a condition in a subject in need of such prevention. Some other embodiments relate to kits for methods of treating a condition in a subject in need of such treatment. For example, some embodiments of the present disclosure provide kits that include one or more of the srRNA constructs, nucleic acid constructs, recombinant cells, and / or pharmaceutical compositions provided and described herein, and instructions for making and using the same.

[0175] In some embodiments, the kits of the present disclosure further comprise one or more means useful for administering any one of the provided srRNA constructs, nucleic acid constructs, recombinant cells, and / or pharmaceutical compositions to a subject. For example, in some embodiments, the kits of the present disclosure further comprise one or more syringes (including pre-filled syringes) and / or catheters (including pre-filled syringes) used to administer any one of the provided srRNA constructs, nucleic acid constructs, recombinant cells, and / or pharmaceutical compositions to a subject. In some embodiments, the kits can have one or more additional therapeutic agents, which can be administered simultaneously or sequentially with other components of the kit for a desired purpose, such as to induce an immune response or to prevent or treat a condition in a subject in need thereof.

[0176] Any of the above kits may further comprise one or more additional reagents, which may be selected from a dilution buffer; a reconstitution solution; a wash buffer; a control reagent; a control expression vector; a negative control; a positive control; and reagents suitable for in vitro production of the srRNA constructs, nucleic acid constructs, recombinant cells, and / or pharmaceutical compositions of the present disclosure provided.

[0177] In some embodiments, the components of the kit may be in separate containers. In some embodiments, the components of the kit may be combined in a single container. Thus, in some embodiments of the present disclosure, the kit includes one or more of the nucleic acid constructs (e.g., vectors or srRNA molecules), recombinant cells, recombinant polypeptides, and / or pharmaceutical compositions provided and described herein in one container (e.g., in a sterile glass or plastic vial) and an additional therapeutic agent in another container (e.g., in a sterile glass or plastic vial).

[0178] In another embodiment, the kit comprises a combination of compositions described herein, including one or more nucleic acid constructs (e.g., vectors or srRNA molecules), recombinant cells, and / or recombinant polypeptides of the present disclosure, combined with one or more additional therapeutic agents, formulated into a single pharmaceutical composition, optionally in a single common container.

[0179] Where the kit includes a pharmaceutical composition for parenteral administration to a subject, the kit can include a device for performing such administration (e.g., an injection device or catheter). For example, the kit can include one or more hypodermic needles or other injection devices as described above that include one or more nucleic acid constructs (e.g., vectors or srRNA molecules), recombinant cells, and / or recombinant polypeptides of the present disclosure.

[0180] In some embodiments, the kit can further include instructions for using the components of the kit to practice the methods disclosed herein. For example, the kit can include a package insert containing information regarding the pharmaceutical compositions and dosage forms in the kit. Generally, such information will assist patients and physicians in effectively and safely using the enclosed pharmaceutical compositions and dosage forms. For example, the package insert may provide the following information regarding the combinations of the present disclosure: pharmacokinetics, pharmacodynamics, clinical trials, efficacy parameters, indications and usage, contraindications, warnings, precautions, side effects, overdosage, appropriate dosage and administration, delivery methods, appropriate storage conditions, references, manufacturer / distributor information, and proprietary information.

[0181] The instructions for carrying out the method are typically recorded on a suitable recording medium. For example, the instructions can be printed on a substrate such as paper or plastic. The instructions can be present in the kit, for example, as a package insert or in the label of the container of the kit or its components (e.g., to the packaging or subpackaging, etc.). The instructions can be present as an electronic storage data file present on a suitable computer-readable storage medium, such as a CD-ROM, diskette, or flash drive. In some examples, the actual instructions are not present in the kit, but a means for obtaining the instructions from a remote source (e.g., via the Internet) can be provided. An example of this embodiment is a kit that includes a web address where the instructions can be viewed and / or downloaded. As with the instructions, the means for obtaining the instructions can also be recorded on a suitable substrate.

[0182] Methods for Inducing an Immune Response or for Preventing or Treating a Condition Administration of any one of the compositions described herein, such as srRNA constructs, nucleic acid constructs, recombinant cells, and / or pharmaceutical compositions, can be used to treat associated health conditions, such as proliferative diseases (such as cancer), infectious diseases (such as acute, chronic, or viral infections), rare diseases, autoimmune diseases, and / or inflammatory diseases. In some embodiments, the srRNA constructs, nucleic acid constructs, recombinant cells, and / or pharmaceutical compositions described herein can be useful for inducing a pharmacodynamic effect in a subject. In some embodiments, the srRNA constructs, nucleic acid constructs, recombinant cells, and / or pharmaceutical compositions described herein can be useful for modulating, e.g., inducing or suppressing, an immune response in a subject in need thereof. In some embodiments, the srRNA constructs, nucleic acid constructs, recombinant cells, and / or pharmaceutical compositions described herein can be incorporated into a therapeutic agent for use in a method of treating a subject who has, is suspected of having, or may be at high risk of developing one or more associated health conditions or diseases. Examples of conditions or diseases include, but are not limited to, cancer, immune diseases, autoimmune diseases, inflammatory diseases, gene therapy, gene replacement, cardiovascular diseases, age-related conditions, rare diseases, acute infections, and chronic infections, etc. In some embodiments, the subject is a patient under the care of a physician.

[0183] Examples of autoimmune diseases suitable for the methods of the present disclosure include rheumatoid arthritis, osteoarthritis, Still's disease, familial Mediterranean fever, systemic sclerosis, multiple sclerosis, ankylosing spondylitis, Hashimoto's disease, systemic lupus erythematosus, Sjogren's syndrome, diabetic retinopathy, diabetic vasculopathy, diabetic neuralgia, insulitis, psoriasis, alopecia areata, warm and cold autoimmune hemolytic anemia (AIHA), pernicious anemia, acute inflammatory diseases, autoimmune adrenalitis, chronic inflammatory demyelinating polyneuropathy (CIDP), Lambert-Eaton syndrome, lichen sclerosus, Lyme disease, Graves' disease, Behcet's disease, Meniere's disease, reactive arthritis (Reiter's syndrome), Churg-Strauss syndrome, Cogan's syndrome, CREST syndrome, pemphigus vulgaris and pemphigus foliaceus, bullous pemphigoid, polymyalgia rheumatica, polymyositis, primary biliary cirrhosis , pancreatitis, peritonitis, psoriatic arthritis, rheumatic fever, sarcoidosis, Sjorgensen's syndrome, scleroderma, celiac disease, stiff-man syndrome, Takayasu's arteritis, transient gluten intolerance, autoimmune uveitis, vitiligo, polychondritis, dermatitis herpetiformis (DH) or Duhring's disease, fibromyalgia, Goodpasture's syndrome, Guillain-Barré syndrome, Hashimoto's thyroiditis, autoimmune hepatitis, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, myasthenia gravis, immune complex disease, glomerulonephritis, polyarteritis nodosa, antiphospholipid syndrome, polyglandular autoimmune syndrome, idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura (ITP), urticaria, autoimmune infertility, juvenile rheumatoid arthritis, sarcoidosis, and autoimmune cardiomyopathy.

[0184] Non-limiting examples of infectious diseases suitable for the methods of the present disclosure include infections caused by viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis B virus (HCV), cytomegalovirus (CMV), respiratory syncytial virus (RSV), human papillomavirus (HPV), Epstein-Barr virus (EBV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome (MERS), influenza virus, and Ebola virus. Additional infectious diseases suitable for the methods of the present disclosure include infections with intracellular parasites such as Leishmania, Rickettsia, Chlamydia, Coxiella, Plasmodium, Brucella, Mycobacteria, Listeria, Toxoplasma, and Trypanosoma. In some embodiments, the srRNA constructs, nucleic acid constructs, recombinant cells, and / or pharmaceutical compositions may be useful for the treatment and / or prevention of immune, autoimmune, or inflammatory diseases.Examples of such diseases include glomerulonephritis, inflammatory bowel disease, nephritis, peritonitis, psoriatic arthritis, osteoarthritis, Still's disease, familial Mediterranean fever, systemic sclerosis and sclerosis, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, acute lung injury, meningitis, encephalitis, uveitis, multiple myeloma, glomerulonephritis, nephritis, asthma, arteriosclerosis, leukocyte adhesion deficiency, multiple sclerosis, Raynaud's syndrome, Sjogren's syndrome, juvenile-onset diabetes, Reiter's disease, Behcet's disease, immune complex nephritis, IgA nephropathy, IgM polyneuropathy, immune-mediated thrombocytopenia, hemolytic anemia, myasthenia gravis, These include lupus nephritis, lupus erythematosus, rheumatoid arthritis (RA), ankylosing spondylitis, pemphigus, Graves' disease, Hashimoto's thyroiditis, small vasculitis, Omenn's syndrome, chronic renal failure, autoimmune thyroid disease, acute infectious mononucleosis, HIV, herpes virus-related diseases, human viral infections, coronaviruses, other enteroviruses, herpes viruses, influenza viruses, parainfluenza viruses, respiratory syncytial viruses, or adenovirus infections, bacterial pneumonia, wounds, sepsis, stroke / cerebral edema, ischemia-reperfusion injury, and hepatitis C.

[0185] Non-limiting examples of inflammation suitable for the methods of the present disclosure include inflammatory diseases such as asthma, inflammatory bowel disease (IBD), chronic colitis, splenomegaly, and rheumatoid arthritis.

[0186] In one aspect, provided herein is a method for inducing a pharmacodynamic effect in a subject, the method comprising administering to the subject a composition comprising one or more of the following: (a) a replicon, such as a self-replicating RNA (srRNA) construct described herein; (b) a nucleic acid described herein; (c) a recombinant cell described herein; and (d) a pharmaceutical composition described herein. In some embodiments, the pharmacodynamic effect comprises eliciting an immune response in the subject.

[0187] In another aspect, provided herein is a method for preventing or treating a condition in a subject, the method comprising prophylactically or therapeutically administering to the subject a composition comprising one or more of the following: (a) a replicon, such as a self-replicating RNA (srRNA) construct described herein; (b) a nucleic acid described herein; (c) a recombinant cell described herein; and (d) a pharmaceutical composition described herein.

[0188] Non-limiting preferred embodiments of the methods described herein for inducing a pharmacodynamic effect and / or preventing and / or treating a health condition in a subject may include one or more of the following features: In some embodiments, the administered composition induces production of one or more proinflammatory molecules in the subject. In some embodiments, the one or more proinflammatory molecules include interferon gamma (IFNγ), a cytokine, TNF-α, GM-CSF, MIP1α, granzyme B, granzyme A, perforin, or any combination thereof. In some embodiments, the subject has previously been treated with one or more therapies and has acquired at least partial resistance to the one or more therapies. In some embodiments, at least one of the one or more therapies includes a small molecule. In some embodiments, the health condition is a proliferative disease, an inflammatory disease, an autoimmune disease, or a microbial infection. In some embodiments, the subject has or is suspected of having a health condition associated with a proliferative disease, an inflammatory disease, an autoimmune disease, or a microbial infection. In some embodiments, the proliferative disease is cancer. In some embodiments, the cancer is breast cancer.

[0189] Non-limiting examples of breast cancer suitable for the methods of the present disclosure include ductal carcinoma, lobular carcinoma, undifferentiated carcinoma, lobular sarcoma, angiosarcoma, and primary breast lymphoma. Breast cancer can include stage I, stage II, stage IIIA, stage IIIB, stage IIIC, and stage IV breast cancer. Ductal carcinoma can include invasive carcinoma type, invasive intraepithelial carcinoma with predominant intraglandular component, inflammatory breast carcinoma, and carcinoma of the ducts. Ductal carcinoma can include invasive lobular carcinoma with predominant intraepithelial component, invasive lobular carcinoma, and invasive lobular carcinoma. Breast cancer can include Paget's disease, extramammary Paget's disease, Paget's disease with intraglandular carcinoma, and Paget's disease with invasive ductal carcinoma. Breast cancer can include breast neoplasms with histological and ultrastructural heterogeneity (e.g., mixed cell types). Breast cancer can be classified into molecular subtypes: basal-like, luminal A, luminal B, ERBB2 / Her2+, or normal breast-like.

[0190] In some embodiments, the compositions of the present disclosure may be formulated to be compatible with its intended route of administration. For example, the srRNA constructs, nucleic acid constructs, recombinant cells, and / or pharmaceutical compositions of the present disclosure may be administered orally, by inhalation, or via parenteral routes. Examples of parenteral routes of administration include intramuscular, intratumoral, intraocular, intravenous, intranodal, intradermal, subcutaneous, transdermal (topical), transmucosal, intravaginal, and rectal administration. In some embodiments, the compositions are administered intramuscularly. In some embodiments, the compositions are administered intratumorally. Solutions or suspensions used for parenteral application may contain the following components: a sterile diluent such as water for injection, saline, fixed oils, polyethylene glycol, glycerin, propylene glycol, or other synthetic solvents; antibacterial agents such as benzyl alcohol or methylparaben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetate, citrate, phosphate, Tris, sucrose, and agents for adjusting tonicity such as sodium chloride or glucose. The pH can be adjusted (e.g., to about 7.2 to 7.8, such as 7.5, for example) with an acid or base, such as monobasic and / or dibasic sodium phosphate, hydrochloric acid, or sodium hydroxide. Parenteral formulations can be enclosed in ampoules, disposable syringes, or multiple dose vials made of glass or plastic.

[0191] Compositions, such as srRNA constructs, nucleic acid constructs, recombinant cells, and / or pharmaceutical compositions described herein, can be administered at least once a day to at least once a week, for example, once every other day. Treatment of a subject with a therapeutically effective amount of a subject srRNA construct, nucleic acid construct, recombinant cell, and / or pharmaceutical composition of the present disclosure can include a single treatment or a series of treatments. In some embodiments, the composition is administered at weekly intervals, for example, 1-2, 2-3, or 3-4 doses, at 1-2, 2-3, or 3-4 week intervals. Additional doses can be administered thereafter every month, 2 months, 3 months, or 4 months. In some embodiments, three intramuscular doses can be administered at 3-4 week intervals, followed by intramuscular doses every 3 months. Alternatively, the composition can be administered at shorter intervals, for example, every 8 hours for 5 days, followed by a rest period of 2-14 days, for example, 9 days, followed by another 5 days every 8 hours. With respect to srRNA constructs and nucleic acid constructs, a therapeutically effective amount (eg, an effective therapeutic amount) of the srRNA constructs and nucleic acid constructs of the present disclosure will vary depending on the srRNA construct and nucleic acid construct selected.

[0192] As noted above, a therapeutically effective amount includes an amount of a therapeutic composition sufficient to promote a particular effect when administered, such as to a subject having, suspected of having, or at risk for a health condition, such as cancer. In some embodiments, an effective amount includes an amount sufficient to prevent or delay the appearance of a disease symptom, alter the course of a disease symptom (such as, but not limited to, slowing the progression of a disease symptom), or reverse a disease symptom.

[0193] A treatment is considered effective if at least any one or all of the signs or symptoms of the disease are improved or alleviated. Efficacy can also be measured by assessing that the individual is not worsening (e.g., the progression of the disease is stopped or at least delayed), based on hospitalization or the need for medical intervention. Methods for measuring these indicators are known to those skilled in the art and / or described herein. Treatment includes any treatment of disease in a subject or animal (some non-limiting examples include humans or mammals), including: (1) inhibiting the disease, e.g., stopping or slowing the progression of symptoms; (2) relieving the disease, e.g., causing the symptoms to regress; and (3) preventing symptoms or reducing the likelihood of the symptoms appearing.

[0194] In some embodiments, the srRNA constructs, nucleic acid constructs, recombinant cells, and / or pharmaceutical compositions of the present disclosure may be administered to a subject in a composition with a pharma- ceutically acceptable carrier in an amount effective to stimulate an immune response. Typically, the subject is immunized with an initial series of injections (or by administration via any one of the other routes described below), followed by booster immunizations to enhance protection from the initial series. In the initial series of injections and subsequent booster immunizations, administrations are given in amounts and for periods of time necessary to stimulate an immune response in the subject. In some embodiments of the disclosed methods, the subject is a mammal. In some embodiments, the mammal is a human subject.

[0195] As mentioned above, pharma- ceutically acceptable carriers suitable for injectable use include sterile aqueous solutions (if water soluble) or dispersions, and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In these cases, the compositions must be sterile and fluid to the extent that good injectability exists. Furthermore, the compositions must be stable under the conditions of manufacture and storage and preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium, including water, ethanol, polyol (such as glycerol, propylene glycol, and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by maintaining the required particle size in the case of dispersions, and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.

[0196] Sterile injectable solutions can be prepared by incorporating the required amount of srRNA constructs, nucleic acid constructs, recombinant cells, and / or pharmaceutical compositions in the appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.

[0197] Once the srRNA constructs, nucleic acid constructs, recombinant cells, and / or pharmaceutical compositions are properly protected, as described above, they may be orally administered, for example, with an inert diluent or an assimilable edible carrier. The srRNA constructs, nucleic acid constructs, recombinant cells, and / or pharmaceutical compositions and other ingredients may be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the individual's diet. For oral therapeutic administration, the active compound may be combined with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.

[0198] Additional Therapy In some embodiments, the compositions of the present disclosure are administered to a subject individually as a single therapy (monotherapy) or as a first therapy in combination with at least one additional therapy (e.g., a second therapy). In some embodiments, the second therapy is selected from the group consisting of chemotherapy, radiation therapy, immunotherapy, hormone therapy, toxin therapy, targeted therapy, and surgery. In some embodiments, the second therapy is selected from the group consisting of chemotherapy, radiation therapy, immunotherapy, hormone therapy, toxin therapy, or surgery. In some embodiments, the first therapy is administered in combination with the second therapy. In some embodiments, the first therapy is administered simultaneously with the second therapy. In some embodiments, the first therapy is administered sequentially with the second therapy. In some embodiments, the first therapy is administered prior to the second therapy. In some embodiments, the first therapy is administered after the second therapy. In some embodiments, the first therapy is administered prior to and / or after the second therapy. In some embodiments, the first therapy is administered in rotation with the second therapy. In some embodiments, the administration of the first therapy and the administration of the second therapy are administered together in a single formulation. EXAMPLES

[0199] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, cell biology, biochemistry, nucleic acid chemistry, and immunology, which are well known to those of skill in the art. Such techniques are described, for example, in Sambrook, J., & Russell, DW (2012). Molecular Cloning: A Laboratory Manual (4th ed.). Cold Spring Harbor, NY: Cold Spring Harbor Laboratory and Sambrook, J., & Russell, DW (2001). Molecular Cloning: A Laboratory Manual (3rd ed.). Cold Spring Harbor, NY: Cold Spring Harbor Laboratory (collectively referred to herein as "Sambrook"); Ausubel, FM (1987). Current Protocols in Molecular Biology. New York, NY: Wiley (including supplements up to 2014); Bollag, DM et al. (1996). Protein Methods. New York, NY: Wiley-Liss; Huang, L. et al. (2005). Nonviral Vectors for Gene Therapy. San Diego: Academic Press; Kaplitt, MG et al. (1995). Viral Vectors: Gene Therapy and Neuroscience Applications. San Diego, CA: Academic Press;Lefkovits, I. (1997). The Immunology Methods Manual: The Comprehensive Sourcebook of Techniques. San Diego, CA: Academic Press;Doyle, A. et al. (1998). Cell and Tissue Culture: Laboratory Procedures in Biotechnology.New York, NY: Wiley; Mullis, KB, Ferre, F. & Gibbs, R. (1994). PCR: The Polymerase Chain Reaction. Boston: Birkhauser Publisher; Greenfield, EA (2014). Antibodies: A Laboratory Manual (2nd ed.). New York, NY: Cold Spring Harbor Laboratory Press; Beaucage, SL et al. (2000). Current Protocols in Nucleic Acid Chemistry. New York, NY: Wiley (including supplements up to 2014); and Makrides, SC (2003). Gene Transfer and Expression in Mammalian Cells. Amsterdam, NL: Elsevier Sciences BV; the disclosures of which are incorporated herein by reference.

[0200] Further embodiments are disclosed in more detail in the following examples, which are provided for illustrative purposes and are not intended to limit the scope of the disclosure or claims in any way.

[0201] Example 1 Construction of EEEV vectors encoding srRNA constructs for vaccine applications This example describes experiments performed to construct a base (e.g., heterologous gene-free) EEEV vector that was used to construct EEEV vectors expressing one or more genes of interest (e.g., ESR1 or a variant thereof, PI3K or a variant thereof, HER2 or a variant thereof, and HER3 or a variant thereof).

[0202] A base EEEV vector (i.e., without the heterologous gene of interest) was constructed as follows: the base EEEV vector was synthesized de novo (Twist Bioscience) in four ~4 kb pieces from the reference sequence (Genbank EF151502) with some modifications. Restriction enzyme cleavage sites were eliminated by incorporating silent mutations G301A, A3550C, G4516A, G5725A, and G7399A. A unique restriction enzyme cleavage site (SpeI, 5'-A'CTAG,T-3') (5'A in the sequence corresponds to the position of the ATG start codon of the structural polyprotein and 3'T corresponds to the position of the TAA stop codon of the structural polyprotein) was incorporated in place of the coding sequence of the native EEEV structural gene. A 5' adaptor sequence (5'-CTGGAGACGTGGAGGAGAACCCTGGACCT-3'; SEQ ID NO:5) was inserted upstream of the SpeI site and a 3' adaptor sequence (5'-GACCGCTACGCCCCAATGACCCGACCAGC-3'; SEQ ID NO:6) was inserted downstream of the SpeI site for use in the subsequent Gibson Assembly® procedure (Gibson et al., Nat. Methods 6, 343-345, 2009). A bacteriophage T7 RNA polymerase promoter (5'-TAATACGACTCACTATAG-3'; SEQ ID NO:7) was included upstream of the EEEV genomic sequence, downstream containing a poly(A) sequence followed by a SapI site, which cleaves upstream of the recognition site. Immediately downstream of the SapI site is a T7 terminator sequence (5'-AACCCCTCTCTAAACGGAGGGGTTTTTTT-3'; SEQ ID NO:8), followed by a unique restriction site (NotI, 5'-GC'GGCC,GC-3'). The above portions were combined in a five-fragment Gibson Assembly® reaction to generate an EEEV-based vector from the linearized pYL backbone and the four synthetic fragments.

[0203] EEEV vectors containing heterologous genes were constructed as follows: The base EEEV base vector was linearized by SpeI digestion. ESR1, PI3K, HER2, and HER3 variants were codon optimized / refactored in silico for human expression and synthesized de novo with the EMCV IRES (GeneArt, IDT). The synthesis products were amplified with primers that added 5' and 3' adapter sequences to the gene ends or with primers that added P2A sequences and / or sequences homologous to the adjacent gene insert. The digestion and PCR products were combined using the Gibson Assembly® procedure to obtain the final vectors.

[0204] Example 2 In vitro evaluation of EEEV vectors encoding vaccine srRNA constructs This example describes the results of in vitro experiments performed to assess the expression levels of the synthetic EEEV srRNA constructs described in Example 1 above and to examine any differences in their behavior (e.g., replication and protein expression).

[0205] In vitro transcription: RNA was prepared by in vitro transcription from SapI-linearized plasmid templates using bacteriophage T7 polymerase with 5'ARCA cap (HiScribe™ T7 ARCA mRNA Kit, NEB) or without capping (HiScribe™ T7 High Yield RNA Synthesis Kit, NEB), followed by addition of 5' Cap 1 (Vaccinia Capping System, mRNA Cap 2'-O-Methyltransferase, NEB). RNA was then purified using phenol / chloroform extraction or column purification (Monarch® RNA Cleanup Kit, NEB). RNA concentration was measured by absorbance at 260 nm (Nanodrop, Thermo Fisher Scientific).

[0206] Replication: RNA was transfected by electroporation into BHK-21 or Vero cells (e.g., 4D-Nucleofector™, Lonza). 15-22 hours after transfection, cells were fixed and permeabilized (eBioscience™ Foxp3 / Transcription Factor Staining Buffer Set, Invitrogen), stained with a PE-conjugated anti-dsRNA mouse monoclonal antibody (J2, Scicons), and the frequency of dsRNA+ cells and the mean fluorescence intensity (MFI) of dsRNA in individual cells were quantified by fluorescent flow cytometry.

[0207] Protein expression: RNA was transformed by electroporation into BHK-21 or Vero cells (e.g., 4D-Nucleofector™, Lonza). ESR1: Cells were harvested 15-22 hours after transformation and lysed in RIPA buffer. Lysates were normalized for protein concentration, then immunoblotted with anti-ERα rabbit antibody (A300-497A, Bethyl) and imaged with AF800-conjugated anti-rabbit goat antibody (A32735, Thermo) (Figure 3A). Expression levels were normalized using the fluorescent signal from a cell sample transformed with a synthetic single-gene EEEV replicon expressing ESR1 to assess relative ESR1 expression from a panel of two-gene and four-gene replicons (Figure 3B). PI3K: Cells were harvested 15-22 hours after transformation and lysed in RIPA buffer. Lysates were normalized for protein concentration, then immunoblotted using anti-PI3KCA rabbit antibody (PA587398, Thermo) as a probe and imaged with AF800-conjugated anti-rabbit goat antibody (A32735, Thermo) (Figure 3C). Expression levels were normalized using the fluorescent signal from cell samples transformed with a synthetic single-gene EEEV replicon expressing PI3K to assess relative PI3K expression from a panel of two-gene and four-gene replicons (Figure 3D). HER2: 15-22 hours after transformation, cells were fixed and permeabilized (eBioscience™ Foxp3 / Transcription Factor Staining Buffer Set, Invitrogen) and stained with AF488-conjugated anti-HER2 mouse monoclonal antibody (24D2, Biolegend). The mean fluorescence intensity (MFI) of AF488 was used as a readout for HER2 expression. Expression levels were normalized using the MFI of cells transformed with a synthetic single-gene EEEV replicon expressing HER2 to assess relative HER2 expression from the panel of two-gene and four-gene replicons ( Fig. 3E ).HER3: 15-22 hours after transduction, cells were fixed and permeabilized (eBioscience™ Foxp3 / Transcription Factor Staining Buffer Set, Invitrogen) and stained with an APC-conjugated anti-HER3 mouse monoclonal antibody (IB4C3, Biolegend). The mean fluorescence intensity (MFI) of APC was used as a readout for HER3 expression. Expression levels were normalized using the MFI of cells transformed with a synthetic single-gene EEEV replicon expressing HER3 to assess relative HER3 expression from panels of two- and four-gene replicons (Figure 3F). Normalized ESR1, PI3K, HER2, and HER3 expression data from the four-gene replicons were visualized on spider graphs (Figure 3G).

[0208] Example 3 In vivo evaluation of EEEV vectors encoding vaccine srRNA constructs This example describes the results of in vivo experiments performed to assess any differences in immune responses following vaccination with the synthetic EEEV replicon constructs described herein (e.g., both unformulated and LNP-formulated vectors).

[0209] In these experiments, a synthetic replicon construct derived from EEEV strain FL93-939 was designed and subsequently evaluated.

[0210] Mice and Injections. BALB / c mice were purchased from Charles River Labs, Envigo, or Jackson Laboratories. On the day of dosing, 0.01-10 μg of material was injected intramuscularly into one quadriceps or split into both quadriceps. Vectors were administered unformulated, in saline, or formulated in LNP. Animals were weighed and other general observations were made throughout the study. For immunogenicity studies, animals were dosed on day 0 only, or on days 0 and 21.

[0211] LNP formulation. Replicon RNA was formulated into lipid nanoparticles using a microfluidic mixer and analyzed for particle size, dynamic light scattering polydispersity, and encapsulation efficiency. Lipids were suspended in ethanol. For C12-200, RNA was suspended in 10 mM citrate buffer (pH 5.0) at a concentration of 172 μg / ml and mixed at a flow rate of 3:1 (aqueous:organic). For L2, RNA was suspended in 250 mM NaOAc (pH 4.0) at a concentration of 82 μg / ml and mixed at a flow rate of 3:1 (aqueous:organic).

[0212] To measure the magnitude of ESR1-, HER2-, and HER3-specific T cell responses, IFNγ ELISpot assays were performed using the Mouse IFNγ ELISpot PLUS Kit (HRP) (MabTech) according to the manufacturer's instructions. Briefly, splenocytes were isolated and cultured at 5 × 10 cells / mL in medium containing ESR1-, HER2-, and HER3-derived peptides, PMA / ionomycin as a positive control, or DMSO as a mock stimulation. 6 The cells were resuspended at a concentration of 1000 cells / mL.

[0213] Linker Evaluation Figure 2 shows the results of intramuscular injection of single gene replicon RNAs encoding ESR1 mutations linked together in different orders and with different linkers, followed 14 days later by mouse IFNγ detection ELISpot assay to measure the spot forming units corresponding to responder splenic T cells. AAY, EAAAK (SEQ ID NO: 1), RVRR (SEQ ID NO: 2), GGGGS (SEQ ID NO: 3), and GPGPG (SEQ ID NO: 4) linkers were tested in ESR1 antigen cassettes containing K303R, E380Q, Y537C, Y537S, Y537N, and D538G mutations in various orders. The columns for each cassette correspond to the stimulation conditions with a single peptide in the following order: K303R, E380Q, Y537N, Y537S, Y537C, D538G, wild type ESR1, and medium. The total T cell response (plotted as spot forming unit counts per million cells) is shown on the Y axis. The GGGGS (SEQ ID NO:3) linker sequence generated the most robust T cell responses.

[0214] Assessment of gene number and order Figure 4 shows mouse IFNγ detection ELISpot assays performed 35 days after two intramuscular injections of replicon RNA encoding ESR1, HER2, and HER3 to measure spot forming units corresponding to responder splenic T cells. Various constructs in single-, two-, or four-gene forms with ESR1, PI3K, HER2, and HER3 in different orderings and linkage sequences were tested to determine which constructs in gene configurations produced the most robust T cell responses upon stimulation. The Y-axis indicates the total T cell response. PI3K responses were not measured in this experiment because PI3K does not generate a response in BALB / c mice.

[0215] Evaluation of gene sequence and lipid formulations Replicon RNA encoding ESR1, PI3K, HER2, and HER3 was injected intramuscularly twice in saline or formulated in two different LNP compositions, L1 or L2, and 35 days later, a mouse IFNγ detection ELISpot assay was performed to measure spot forming units corresponding to responder splenic T cells, as shown in Figure 6. Different four-gene constructs with different replicon vector backbones were tested to determine which RNA replicon vector and formulation provided the most robust T cell response upon stimulation.

[0216] Example 4 Efficacy against estrogen receptor-positive breast cancer Figure 7 shows two efficacy models that mimic two clinical scenarios. In the therapeutic model, a tumor cell line expressing the resistance mutation targeted by the vaccine is first implanted. The vaccine is then administered. This simulates a scenario in which a patient with a pre-existing mutation is treated. In the preventive model, vaccination is administered before implantation of a tumor cell line encoding the resistance mutation contained in the vaccine. This scenario mimics treating a patient before acquired mutations emerge. Administration of replicon RNA encoding the mutations expressed by the tumor cell line to mice should elicit a robust T cell response, thereby slowing tumor growth. If tumor growth is not delayed, the tumor cell line has likely evolved to lose the targeted mutation, indicating that the replicon RNA was able to provide selective pressure by the immune system to lose the activating mutation.

[0217] Example 5 Construction of Alphavirus Vectors Encoding srRNA Constructs for Biotherapeutic Applications This example describes experiments performed to construct a base (e.g., heterologous gene-free) alphavirus vector that was used to construct vectors expressing one or more genes of interest (e.g., IL-12 p35 subunit or a functional variant thereof, IL-12 p40 subunit or a functional variant thereof, and IL-1RA or a functional variant thereof).

[0218] EEEV-based vector A base EEEV vector (i.e., without the heterologous gene of interest) was constructed as follows: the base EEEV vector was synthesized de novo in four ~4 kb pieces (Twist Bioscience) from a reference sequence (Genbank EF151502) with some modifications. Restriction enzyme cleavage sites were eliminated by incorporating silent mutations G301A, A3550C, G4516A, G5725A, and G7399A. A unique restriction enzyme cleavage site (SpeI, 5'-A'CTAG,T-3') (5'A in the sequence corresponds to the position of the ATG start codon of the structural polyprotein and 3'T corresponds to the position of the TAA stop codon of the structural polyprotein) was incorporated in place of the coding sequence of the native EEEV structural gene. A 5' adaptor sequence (5'-CTGGAGACGTGGAGGAGAACCCTGGACCT-3'; SEQ ID NO:5) was inserted upstream of the SpeI site and a 3' adaptor sequence (5'-GACCGCTACGCCCCAATGACCCGACCAGC-3'; SEQ ID NO:6) was inserted downstream of the SpeI site for use in the subsequent Gibson Assembly® procedure (Gibson et al., Nat. Methods 6, 343-345, 2009). A bacteriophage T7 RNA polymerase promoter (5'-TAATACGACTCACTATAG-3'; SEQ ID NO:7) was included upstream of the EEEV genomic sequence, downstream containing a poly(A) sequence followed by a SapI site, which cleaves upstream of the recognition site. Immediately downstream of the SapI site is a T7 terminator sequence (5'-AACCCCTCTCTAAACGGAGGGGTTTTTTT-3'; SEQ ID NO:8), followed by a unique restriction site (NotI, 5'-GC'GGCC,GC-3'). The above portions were combined in a five-fragment Gibson Assembly® reaction to generate an EEEV-based vector from the linearized pYL backbone and the four synthetic fragments.

[0219] CHIKV base vector The base CHIKV S27 vector was de novo synthesized in four approximately 4 kb pieces (Twist Bioscience, Thermo Fisher GeneArt) from a reference sequence (Genbank AF369024) that had a silent A5366G mutation and replaced the coding sequence of the CHIKV structural gene with a unique restriction enzyme cleavage site (SpeI, 5'-A'CTAG,T-3') (5'A corresponds to the position of the ATG start codon of the structural polyprotein, and 3'T corresponds to the position of the TAA stop codon of the structural polyprotein). A 5' adapter sequence (5'-CTGGAGACGTGGAGGAGAACCCTGGACCT-3'; SEQ ID NO: 5) was inserted upstream of the SpeI site, and a 3' adapter sequence (5'-GACCGCTACGCCCCAATGACCCGACCAGC-3'; SEQ ID NO: 6) was inserted downstream of the SpeI site for use in the subsequent Gibson Assembly® procedure. A bacteriophage T7 RNA polymerase promoter (5'-TAATACGACTCACTATAG-3'; SEQ ID NO:7) was included upstream of the CHIKV genomic sequence, followed downstream by a poly(A) sequence followed by a SapI site (which cleaves upstream of the recognition site). Immediately downstream of the SapI site was the T7 terminator sequence (5'-AACCCCTCTCTAAACGGAGGGGTTTTTTT-3'; SEQ ID NO:8) followed by a unique restriction enzyme cleavage site (NotI, 5'-GC'GGCC,GC-3'). The above portions were combined in a five-fragment Gibson Assembly® reaction to generate the CHIKV S27-based vector from the linearized pYL backbone and the four synthetic fragments.

[0220] A CHIKV DRDE-based vector was similarly constructed from the reference sequence (Genbank EF210157) except that the S27 3'UTR was used instead of the DRDE 3'UTR.

[0221] SINV-based vectors The base SINV Girdwood vector was synthesized de novo in four ~4 kb pieces (Twist Bioscience, Thermo Fisher GeneArt) from the Girdwood strain reference sequence (Genbank MF459683) in which the coding sequence of the SINV structural genes was replaced with a unique restriction enzyme cleavage site (SpeI, 5'-A'CTAG,T-3') (where 5'A is the next nucleotide of the P2A sequence following nucleotide 93 of the structural polyprotein gene and 3'T coincides with the position of the stop codon TGA of the structural polyprotein). A bacteriophage T7 RNA polymerase promoter (5'-TAATACGACTCACTATAG-3'; SEQ ID NO: 7) was included upstream of the SINV genomic sequence, and downstream contained a poly(A) sequence followed by a SapI site (which cleaves upstream of the recognition site). Immediately downstream of the SapI site is a T7 terminator sequence (5'-AACCCCTCTCTAAACGGAGGGGTTTTTTT-3'; SEQ ID NO:8), followed by a unique restriction site (NotI, 5'-GC'GGCC,GC-3'). The above portions were combined in a five-fragment Gibson Assembly® reaction (e.g., linearized pYL backbone and the four synthetic fragments above) to generate the SINV Girdwood-based vector.

[0222] The base SINV AR86 vector was similarly constructed from the reference sequence (Genbank U38305) except that the nsP2 coding sequence was obtained from the Girdwood reference sequence.

[0223] VEE-based Vector The base VEE vector was de novo synthesized in four approximately 4 kb pieces (Twist Bioscience, Thermo Fisher GeneArt) from the TC-83 strain reference sequence (Genbank L01443) carrying a silent A2087G mutation and replacing the coding sequence of the VEE structural gene with a unique restriction enzyme cleavage site (SpeI, 5'-A'CTAG,T-3') (where 5'A is the next nucleotide of the P2A sequence following nucleotide 93 of the structural polyprotein gene and 3'T corresponds to the position of the stop codon TGA of the structural polyprotein). A 5' adaptor sequence (5'-CTGGAGACGTGGAGGAGAACCCTGGACCT-3'; SEQ ID NO:5) was inserted upstream of the SpeI site and a 3' adaptor sequence (5'-GACCGCTACGCCCCAATGACCCGACCAGC-3'; SEQ ID NO:6) was inserted downstream of the SpeI site for use in the subsequent Gibson Assembly® procedure. A bacteriophage T7 RNA polymerase promoter (5'-TAATACGACTCACTATAG-3'; SEQ ID NO:7) was included upstream of the VEE genomic sequence, followed downstream by a poly(A) sequence followed by a SapI site (which cleaves upstream of the recognition site). Immediately downstream of the SapI site was the T7 terminator sequence (5'-AACCCCTCTCTAAACGGAGGGGTTTTTTT-3'; SEQ ID NO:8) followed by a unique restriction enzyme cleavage site (NotI, 5'-GC'GGCC,GC-3'). The above portions were combined in a five-fragment Gibson Assembly® reaction (e.g., linearized pYL backbone and the four synthetic fragments above) to generate the VEE-based vector.

[0224] Final Vector Construction of vectors containing heterologous genes was performed as follows: Empty base vector was linearized by SpeI digestion. IL-12A, IL12-B, and IL-1RN genes were codon optimized / refactored in silico for human expression and synthesized de novo with the EMCV IRES (IDT). The synthesis products were amplified with primers that added 5' and 3' adapter sequences to the gene ends or with primers that added P2A sequences and / or sequences homologous to the adjacent gene insert. Digestion and PCR products were combined using the Gibson Assembly® procedure to obtain the final vectors.

[0225] Example 6 In vitro evaluation of EEEV vectors encoding biotherapeutic srRNA constructs This example describes the results of in vitro experiments performed to assess the expression levels of the synthetic srRNA constructs described in Example 5 above and to examine any differences in their behavior (e.g., replication and protein expression).

[0226] In Vitro Transcription: RNA was prepared by in vitro transcription from SapI-linearized plasmid templates using bacteriophage T7 polymerase with 5'ARCA cap (HiScribe™ T7 ARCA mRNA Kit, NEB) or without cap (HiScribe™ T7 High Yield RNA Synthesis Kit, NEB), followed by addition of 5' Cap 1 (Vaccinia Capping System, mRNA Cap 2'-O-Methyltransferase, NEB). RNA was then purified using phenol / chloroform extraction or column purification (Monarch® RNA Cleanup Kit, NEB). RNA concentration was measured by absorbance at 260 nm (Nanodrop, Thermo Fisher Scientific).

[0227] Replication: RNA was transfected by electroporation into BHK-21 or Vero cells (e.g., 4D-Nucleofector™, Lonza). 15-22 hours after transfection, cells were fixed and permeabilized (eBioscience™ Foxp3 / Transcription Factor Staining Buffer Set, Invitrogen), stained with a PE-conjugated anti-dsRNA mouse monoclonal antibody (J2, Scicons), and the frequency of dsRNA+ cells and the mean fluorescence intensity (MFI) of dsRNA in individual cells were quantified by fluorescent flow cytometry.

[0228] Protein Expression by ELISA:

[0229] Human IL-12p70 and IL-1RA were detected in BHK-21 cells electroporated with 500 ng of srRNA single or multi-gene constructs. Supernatants were collected approximately 24 and 48 hours after transfection and analyzed using RnD Systems' Human IL-12p70 (Cat. No. DY1270) and RnD Systems' Human IL-1ra / IL-1F3 DuoSet ELISA (Cat. No. DY280).

[0230] Biological activity assays:

[0231] Human IL-12p70 and IL-1RA were detected in BHK-21 cells electroporated with 500 ng of srRNA single gene or multigene constructs. Supernatants were collected approximately 24 and 48 hours after transfection and analyzed for IL-12 using the Promega GloMax bioassay (catalog no. JA2601). IL-1RA was analyzed using IL-1β Reporter HEK 293 Cells (Invivogen, hkb-il1bv2) according to the manufacturer's instructions, preincubated with 4 ng / mL IL1β (1 ng / mL final) and transfected BHK cell supernatant.

[0232] Assessment of gene number and order ELISA assays detecting mouse IL-12 and IL-1RA were performed on transfected BHK-21 cells and the results are shown in Figures 8A, 8B, 11A, and 11B. Various constructs, either single gene or multi-gene, with different orderings of IL-12 subunit p35, IL-12 subunit p40, and IL-1RA were tested to determine which genetic construct provided the most robust expression of IL-12 and IL-1RA. The Y-axis shows the concentration of IL-12 or IL-1RA in ng / mL. Figure 10 shows the corresponding IL-12 and IL-1RA concentrations measured from each construct tested.

[0233] BHK-21 cells transfected with various srRNA constructs were tested against reporter cells expressing different cytokine receptors, and mouse IL-12 and IL-1RA in the supernatants were measured to detect biological activity. The results are shown in Figures 9A, 9B, 12A, and 12B. Figure 13 shows the corresponding IL-12 and IL-1RA biological activity measured from each construct tested.

[0234] Example 7 In vivo evaluation of alphavirus vectors encoding biotherapeutic srRNA constructs This example describes the results of in vivo experiments performed to evaluate the srRNA constructs described herein (e.g., both unformulated and LNP-formulated vectors).

[0235] In these experiments, synthetic srRNA constructs derived from various alphavirus strains were designed and then evaluated.

[0236] Mice and Injections. BALB / c mice were purchased from Charles River Labs, Envigo, or Jackson Laboratories. On the day of dosing, 0.01-40 μg of material was injected intramuscularly into one quadriceps or split into both quadriceps. Vector was administered unformulated, in saline, or formulated in LNP. Animals were weighed and other general observations were made throughout the study. For pharmacokinetic studies, animals were dosed only on day 0.

[0237] LNP formulation. Replicon RNA was formulated into lipid nanoparticles using a microfluidic mixer and analyzed for particle size, dynamic light scattering polydispersity, and encapsulation efficiency. Lipids were suspended in ethanol. For L1, RNA was suspended in 10 mM citrate buffer (pH 5.0) at a concentration of 172 μg / ml and mixed at a flow rate of 3:1 (aqueous:organic). For L2, RNA was suspended in 250 mM NaOAc (pH 4.0) at a concentration of 82 μg / ml and mixed at a flow rate of 3:1 (aqueous:organic).

[0238] ELISA. To measure serum concentrations of IL-12 and IL-1RA, ELISA assays were performed using Human IL-12 p70 DuoSet ELISA (RnD Systems Cat. No. DY1270) and Human IL-1ra ELISA Kit (Abcam, ab211650) according to the manufacturer's instructions.

[0239] Evaluation of gene sequence and lipid formulations The top two multigene constructs obtained from the in vitro assay were then tested in six different srRNA vectors for protein expression in vivo in mouse serum, and the results are shown in Figures 14A and 14B. We observed that in some cases, IL-1RA was not detectable, possibly due to the short half-life of the protein.

[0240] The multigene construct was then tested in various formulations and protein expression analyzed in vivo by ELISA, with the results shown in Figures 15A and 15B.

[0241] Example 8 In vivo evaluation of modified srRNA vectors carrying heterologous nonstructural protein genes This example describes the results of in vivo experiments performed to evaluate the functional differences of polypeptide constructs of interest (PCI) expressed from multiple LNP-formulated srRNA expression constructs in eliciting immune responses and establishing immune protection following vaccination.

[0242] In these experiments, synthetic srRNA constructs derived from Venezuelan equine encephalitis virus (VEE.TC83); chikungunya virus strains S27 (CHIK.S27) and DRDE-06 (CHIK.DRDE); Sindbis virus strains Girdwood (SIN.GW) and AR86-Girdwood Hybrid 1 (SIN.AR86); and Eastern equine encephalitis virus (EEE.FL93); were designed and subsequently evaluated.

[0243] Mice and Injections. Female BALB / c mice were purchased from Charles River Labs or Jackson Laboratories. On the day of dosing, 0.15-1.5 μg of material was injected intramuscularly in both quadriceps muscles in divided doses. Vectors were formulated as LNPs. Animals were weighed and otherwise observed throughout the study. For immunogenicity studies, animals were dosed on days 0 and 21. Spleens were harvested on days 14 and / or 35 and serum was isolated on days 14 and / or 35.

[0244] LNP formulation. srRNA was formulated into lipid nanoparticles (LNPs) using a microfluidic mixer and analyzed for particle size, dynamic light scattering polydispersity, and encapsulation efficiency. LNPs are composed of ionizable lipids, cholesterol, PEG-2K, and DOPE.

[0245] ELISpot. To measure the magnitude of antigen-specific T cell responses, IFNγ ELISpot assays were performed using the Mouse IFNγ ELISpot PLUS Kit (HRP) (MabTech) according to the manufacturer's instructions. Briefly, splenocytes were isolated and cultured at 1–5 × 10 cells / mL in medium containing a peptide pool corresponding to rabies virus glycoprotein G, PMA / ionomycin as a positive control, or DMSO as a mock stimulation. 6 The cells were resuspended at a concentration of 1000 cells / mL.

[0246] Antibodies. Neutralizing antibody responses to rabies virus were measured using the Rapid Fluorescent Focus Inhibition Test. Briefly, serum dilutions were mixed with a standard amount of live rabies virus and incubated. If anti-rabies neutralizing antibodies are present, the antibodies will neutralize the virus. Cultured cells were then added and the serum / virus / cells were incubated together. Uncoated (i.e., not neutralized by antibodies) rabies virus will infect the cells and this infection can be visualized by microscopy. Endpoint titers were calculated from the percentage of virus-infected cells observed on the slide.

[0247] The in vivo immunogenicity of multiple srRNAs encoding the viral antigen, rabies virus glycoprotein G, was assessed by examining antigen-specific splenic T cell responses (Figure 16A) by ELISpot and anti-rabies neutralizing antibody titers from serum after two immunizations (Figure 16B). All srRNA immunized groups demonstrated robust T cell responses compared to saline controls (Figure 16A), but responses varied among the srRNA vaccines. Similarly, all srRNA immunized groups demonstrated protective neutralizing antibody titers, with some variation among the srRNA vaccines (Figure 16B).

[0248] While particular options of the present disclosure have been disclosed, it should be understood that various modifications and combinations are possible and are contemplated within the true spirit and scope of the appended claims. Accordingly, no precise limitations to the abstract and disclosure presented herein are intended.

Claims

1. 1. A method for identifying and / or characterizing a self-replicating RNA (srRNA) construct, comprising: a) providing a plurality of srRNA expression constructs, each comprising a coding sequence for a polypeptide construct of interest (PCI) operably inserted into an alphavirus srRNA vector, wherein at least a portion of the coding sequence for an alphavirus structural protein is replaced with the coding sequence for said PCI; b) analyzing the levels and / or functionality of PCIs expressed from said plurality of srRNA expression constructs and identifying one or more candidate PCIs having defined properties; c) incorporating the srRNA expression constructs capable of expressing the candidate PCIs identified in (b) into at least one delivery vehicle to generate a combinatorial collection of delivery systems; and d) analyzing said delivery system for its ability to impart at least one pharmacodynamic effect in a subject and identifying an srRNA expression construct capable of imparting a desired pharmacodynamic effect; A method comprising:

2. The method of claim 1 , wherein the coding sequence for the PCI comprises a coding sequence for a single polypeptide or a coding sequence for multiple polypeptides.

3. The method of claim 2, wherein the coding sequences for the multiple polypeptides are operably linked to each other in a single open reading frame (i.e., in a polycistronic ORF).

4. The method of claim 2 , wherein the multiple polypeptides are operably linked to each other by one or more connector sequences.

5. The method of claim 4 , wherein one connector sequence of the plurality of connector sequences comprises an autoproteolytic peptide sequence.

6. 6. The method of claim 5, wherein the autoproteolytic peptide sequence comprises one or more autoproteolytic cleavage sequences derived from calcium-dependent serine endoprotease (furin), porcine teschovirus-1 2A (P2A), foot and mouth disease virus (FMDV) 2A (F2A), equine rhinitis A virus (ERAV) 2A (E2A), Thosea asigna virus 2A (T2A), cytoplasmic polyhedrosis virus 2A (BmCPV2A), flacherie virus 2A (BmIFV2A), or combinations thereof.

7. The method according to any one of claims 4 to 6, wherein the coding sequences of the multiple polypeptides are operably linked to each other by one or more internal ribosome entry sites (IRES).

8. The method of claim 7 , wherein the one or more IRES are selected from a viral IRES, a cellular IRES, and an artificial IRES.

9. 9. The method of claim 7, wherein the one or more IRES are selected from Kaposi's sarcoma-associated herpesvirus (KSHV) IRES, Hepatitis virus IRES, Pestivirus IRES, Cripavirus IRES, Rhopalosiphum padi virus IRES, fibroblast growth factor IRES, platelet-derived growth factor IRES, vascular endothelial growth factor IRES, insulin-like growth factor IRES, picornavirus IRES, encephalomyocarditis virus (EMCV) IRES, Pim-1 IRES, p53 IRES, Apaf-1 IRES, TDP2 IRES, L-myc IRES, and c-myc IRES.

10. The method of any one of claims 1 to 9, wherein the PCI comprises one or more polypeptides selected from microbial proteins, viral proteins, bacterial proteins, fungal proteins, mammalian proteins, and any combination thereof.

11. The method of any one of claims 1 to 10, wherein the PCI comprises one or more polypeptides selected from an antigenic molecule, a biotherapeutic molecule, or any combination thereof.

12. The method of any one of claims 1 to 11, wherein the PCI comprises one or more antigenic polypeptides selected from tumor-associated antigens, tumor-specific antigens, neoantigens, and any combination thereof.

13. 13. The method of claim 12, wherein the one or more antigenic polypeptides include an estrogen receptor, an intracellular signaling enzyme, and a human epidermal growth receptor.

14. The method of any one of claims 10 to 13, wherein the one or more antigenic polypeptides are selected from ESR1, PI3K, HER2, HER3, any variants thereof, and any combinations thereof.

15. 12. The method of any one of claims 1 to 11, wherein the PCI comprises one or more biotherapeutic polypeptides selected from immunomodulators, angiogenesis regulators, extracellular matrix regulators, metabolic regulators, neuromodulators, and any combination thereof.

16. 16. The method of claim 15, wherein the PCI comprises one or more cytokines selected from chemokines, interferons, interleukins, lymphokines, and tumor necrosis factors.

17. 17. The method of claim 16, wherein the PCI comprises one or more interleukins selected from IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-15, IL-15, IL-17, IL-23, IL-27, IL-35, IFNγ, and any subunits thereof.

18. The method of any one of claims 10 to 17, wherein the one or more biotherapeutic polypeptides are selected from IL-12A, IL-12B, IL-1RA, and any combination thereof.

19. 19. The method of any one of claims 1 to 18, wherein step (a) comprises providing a plurality of srRNA expression constructs, each of which comprises a coding sequence for a variant of PCI.

20. (a) The provision of i) obtaining an alphavirus srRNA expression vector in which at least a portion of the coding sequence for an alphavirus structural protein is replaced with the coding sequence for a polypeptide construct of interest (PCI); and ii) generating a plurality of srRNA expression constructs, each of which comprises a coding sequence for said variant of PCI; 20. The method of claim 19, comprising:

21. (a) The provision of i) obtaining coding sequences for multiple variants of a polypeptide construct of interest (PCI); and ii) generating a plurality of srRNA expression constructs, each comprising a coding sequence for a PCI variant of the plurality of PCI variants from (a) operably inserted into an alphavirus srRNA vector, wherein at least a portion of the coding sequence for an alphavirus structural protein is replaced with the coding sequence for the PCI variant; 20. The method of claim 19, comprising:

22. The method of any one of claims 20 to 21, wherein a PCI variant of the plurality of PCI variants comprises one or more molecular modifications.

23. 23. The method of claim 22, wherein the one or more molecular alterations in the PCI variant are selected from the group consisting of a deletion, a substitution, an insertion, a duplication, a mutation, a frameshift variant, a splice variant, and any combination thereof.

24. The method of any one of claims 22 to 23, wherein the one or more molecular modifications are configured over multiple modification cassettes arranged in tandem along the length of the antigen sequence.

25. 25. The method of claim 24, wherein a modification cassette of the plurality of modification cassettes comprises 1, 2, 3, 4, 5, or more molecular modifications.

26. The method of any one of claims 24 to 25, wherein the multiple modification cassettes are operably linked to each other by one or more linkers.

27. 27. The method of claim 26, wherein one of the one or more linkers comprises a synthetic compound linker or a peptide linker.

28. 28. The method of claim 27, wherein the peptide linker comprises an amino acid sequence selected from the group consisting of AAY, EAAAK (SEQ ID NO: 1), RVRR (SEQ ID NO: 2), GGGGS (SEQ ID NO: 3), and GPGPG (SEQ ID NO: 4).

29. The method according to any one of claims 1 to 28, wherein the analysis of the level and / or functionality of the PCI in step (b) is performed in vitro, in vivo or ex vivo.

30. 30. The method of claim 29, wherein the analysis of the level and / or functionality of the PCI comprises immunoblot analysis, fluorescent flow cytometry analysis, enzyme-linked immunosorbent assay analysis, immunogenicity analysis, bioactivity analysis, and / or efficacy in a disease model.

31. The method of any one of claims 1 to 29, wherein the analysis of the delivery system in step (d) for its ability to impart at least one pharmacodynamic effect is performed in vivo or ex vivo.

32. 32. The method of any one of claims 1 to 31, wherein the at least one pharmacodynamic effect comprises one or more of an immunogenic effect, a biomarker response, a therapeutic effect, a prophylactic effect, a desirable effect, an undesirable effect, a side effect, and an effect in a disease model.

33. 33. The method of claim 32, wherein the at least one pharmacodynamic effect comprises the induction of an immune response.

34. 34. The method of any one of claims 1 to 33, wherein the delivery system comprises a physiological buffer, a liposome, a lipid-based nanoparticle (LNP), a polymeric nanoparticle, a viral replicon particle (VRP), a microsphere, an immune stimulating complex (ISCOM), a conjugate of a bioactive ligand, or any combination thereof.

35. 35. The method of claim 34, wherein the LNP delivery system comprises a cationic lipid, an ionizable cationic lipid, an anionic lipid, or a neutral lipid.

36. 35. The method of claim 34, wherein the LNP delivery system comprises an ionizable cationic lipid selected from the group consisting of ALC-0315, C12-200, LN16, MC3, MD1, SM-102, and any combination thereof.

37. 35. The method of claim 34, wherein the LNPs comprise a cationic lipid selected from the group consisting of 98N12-5, C12-200, C14-PEG2000, DLin-KC2-DMA (KC2), DLin-MC3-DMA (MC3), XTC, MD1, 7C1, and any combination thereof.

38. 35. The method of claim 34, wherein the LNP comprises a neutral lipid selected from the group consisting of DPSC, DPPC, POPC, DOPE, SM, and any combination thereof.

39. 35. The method of claim 34, wherein the LNPs comprise a lipid selected from the group consisting of C12-200, C14-PEG2000, DOPE, DMG-PEG2000, DSPC, DOTMA, DOSPA, DOTAP, DMRIE, DC-cholesterol, DOTAP-cholesterol, GAP-DMOREE-DPyPE, and GL67A-DOPE-DMPE-polyethylene glycol (PEG).

40. 40. The method of any one of claims 34 to 39, wherein the mass ratio of lipid to nucleic acid in the LNP delivery system is from about 100:1 to about 3:1, from about 70:1 to 10:1, or from 16:1 to 4:

1.

41. 41. The method of claim 40, wherein the mass ratio of lipid to nucleic acid in the LNP delivery system is about 16:1 to 4:

1.

42. The method of any one of claims 40 to 41, wherein the mass ratio of lipid to nucleic acid in the LNP delivery system is about 20:

1.

43. The method of any one of claims 40 to 41, wherein the mass ratio of lipid to nucleic acid in the LNP delivery system is about 8:

1.

44. 44. The method of any one of claims 34 to 43, wherein the lipid-based nanoparticles (LNPs) have an average diameter of less than about 1000 nm, less than about 500 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, less than about 50 nm, or less than about 25 nm.

45. 45. The method of claim 44, wherein the LNPs have an average diameter in the range of about 70 nm to 100 nm.

46. 46. ​​The method of claim 45, wherein the LNPs have an average diameter ranging from about 88 nm to about 92 nm, 82 nm to about 86 nm, or about 80 nm to about 95 nm.

47. The method of any one of claims 1 to 46, wherein the recombinant alphavirus srRNA is from a virus belonging to the genus Alphavirus of the family Togaviridae.

48. 48. The method of claim 47, wherein the recombinant alphavirus srRNA is from an alphavirus belonging to the VEEV / EEEV group, or the SFV group, or the SINV group.

49. The alphavirus may be any of Eastern Equine Encephalitis Virus (EEEV), Venezuelan Equine Encephalitis Virus (VEEV), Everglades Virus (EVEV), Mucambo Virus (MUCV), Pixuna Virus (PIXV), Middleburg Virus (MIDV), Chikungunya Virus (CHIKV), O'Nyong-Nyong Virus (ONNV), Ross River Virus (RRV), Barmah Forest Virus (BNV), and others.

49. The method of claim 48, wherein the virus is selected from the group consisting of Bifidobacterium moniliforme virus (BF), Getah virus (GET), Sagiyama virus (SAGV), Bebaru virus (BEBV), Mayaro virus (MAYV), Una virus (UNAV), Sindbis virus (SINV), Aura virus (AURAV), Whataroa virus (WHAV), Babanki virus (BABV), Kyzylagach virus (KYZV), Western equine encephalitis virus (WEEV), Highland J virus (HJV), Fort Morgan virus (FMV), Ndumu virus (NDUV), Madariaga virus (MADV), or Buggy Creek virus.

50. 50. The method of claim 49, wherein the alphavirus is Venezuelan equine encephalitis virus (VEEV), Eastern equine encephalitis virus (EEEV), Chikungunya virus (CHIKV), or Sindbis virus (SINV).

51. 51. The method of any one of claims 1 to 50, wherein the srRNA expression vector is identified as having immune-inducing activity suitable for prophylactic and / or therapeutic use.

52. A self-replicating RNA (srRNA) construct identified according to the method of claims 1-51.

53. 53. A nucleic acid encoding the srRNA construct of claim 52.

54. a) a self-replicating RNA construct according to claim 52; and / or b) a nucleic acid according to claim 53; A recombinant cell comprising:

55. 55. The recombinant cell of claim 54, which is a eukaryotic cell.

56. The recombinant cell according to any one of claims 54 to 55, which is an animal cell.

57. 57. The recombinant cell of claim 56, wherein the animal cell is a vertebrate cell or an invertebrate cell.

58. 57. The recombinant cell of claim 56, wherein the animal cell is a mammalian cell.

59. 57. The recombinant cell of claim 56, wherein the animal cell is an insect cell.

60. 60. The recombinant cell of claim 59, wherein the insect cell is a mosquito cell.

61. 57. The recombinant cell of claim 56, wherein the animal cell is an immune cell.

62. The immune cells include B cells, monocytes, natural killer (NK) cells, natural killer T (NKT) cells, basophils, eosinophils, neutrophils, dendritic cells (DCs), macrophages, regulatory T cells, helper T cells (T H ), cytotoxic T cells (T CTL ), a memory T cell, a gamma delta (γδ) T cell, a hematopoietic stem cell, or a hematopoietic stem cell precursor.

63. 63. The recombinant cell of claim 62, wherein the immune cell is a B cell, a T cell, or a dendritic cell (DC).

64. 64. A cell culture comprising at least one recombinant cell according to any one of claims 54 to 63 and a cell culture medium.

65. a therapeutically acceptable excipient, and a) a self-replicating RNA construct according to claim 52; b) a nucleic acid according to claim 53; and / or b) A recombinant cell according to any one of claims 54 to 63. A composition comprising:

66. 66. The composition of claim 65, wherein the composition is formulated as a vaccine.

67. 67. The composition of claim 66, wherein the vaccine is a therapeutic vaccine.

68. The composition of any one of claims 65 to 67, wherein the composition is formulated as an immunogenic composition.

69. The composition of any one of claims 65 to 66, wherein the composition is formulated as a biotherapeutic.

70. The composition of any one of claims 65 to 69, wherein the composition is formulated with a delivery vehicle into a delivery system.

71. 71. The composition of claim 70, wherein the delivery system comprises a physiological buffer, a liposome, a lipid-based nanoparticle (LNP), a polymeric nanoparticle, a viral replicon particle (VRP), a microsphere, an immune stimulating complex (ISCOM), a conjugate of a bioactive ligand, or any combination thereof.

72. 72. The composition of claim 71, wherein the LNP delivery system comprises a cationic lipid, an ionizable cationic lipid, an anionic lipid, or a neutral lipid.

73. 72. The composition of claim 71, wherein the LNP comprises an ionizable cationic lipid selected from the group consisting of ALC-0315, C12-200, LN16, MC3, MD1, SM-102, and any combination thereof.

74. 72. The composition of claim 71, wherein the LNP comprises a cationic lipid selected from the group consisting of 98N12-5, C12-200, C14-PEG2000, DLin-KC2-DMA (KC2), DLin-MC3-DMA (MC3), XTC, MD1, 7C1, and any combination thereof.

75. 72. The composition of claim 71, wherein the LNP comprises a neutral lipid selected from the group consisting of DPSC, DPPC, POPC, DOPE, SM, and any combination thereof.

76. 72. The composition of claim 71, wherein the LNPs comprise a lipid selected from the group consisting of C12-200, C14-PEG2000, DOPE, DMG-PEG2000, DSPC, DOTMA, DOSPA, DOTAP, DMRIE, DC-cholesterol, DOTAP-cholesterol, GAP-DMORIE-DPyPE, GL67A-DOPE-DMPE-polyethylene glycol (PEG), and any combination thereof.

77. 77. The composition of any one of claims 71 to 76, wherein the mass ratio of lipid to nucleic acid in the LNP delivery system is from about 100:1 to about 3:1, from about 70:1 to 10:1, or from 16:1 to 4:

1.

78. 78. The composition of claim 77, wherein the mass ratio of lipid to nucleic acid in the LNP delivery system is about 16:1 to 4:

1.

79. 79. The composition of claim 78, wherein the mass ratio of lipid to nucleic acid in the LNP delivery system is about 20:

1.

80. 79. The composition of claim 78, wherein the mass ratio of lipid to nucleic acid in the LNP delivery system is about 8:

1.

81. 81. The composition of any one of claims 71-80, wherein the lipid-based nanoparticles (LNPs) have an average diameter of less than about 1000 nm, less than about 500 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, less than about 50 nm, or less than about 25 nm.

82. 82. The composition of claim 81, wherein the LNPs have an average diameter in the range of about 70 nm to 100 nm.

83. 83. The composition of claim 82, wherein the LNPs have an average diameter ranging from about 88 nm to about 92 nm, 82 nm to about 86 nm, or about 80 nm to about 95 nm.

84. 1. A method of inducing a pharmacodynamic effect in a subject, comprising: a) a self-replicating RNA construct according to claim 52; b) a nucleic acid according to claim 53; c) a recombinant cell according to any one of claims 54 to 63; and / or d) a pharmaceutical composition according to any one of claims 65 to 83; administering to the subject a composition comprising:

85. 85. The method of claim 84, wherein the pharmacodynamic effect comprises eliciting an immune response in the subject.

86. 1. A method of preventing or treating a condition in a subject, comprising: a) a self-replicating RNA construct according to claim 52; b) a nucleic acid according to claim 53; c) a recombinant cell according to any one of claims 54 to 63; and / or d) a pharmaceutical composition according to any one of claims 65 to 83; A method comprising prophylactically or therapeutically administering to said subject a composition comprising:

87. 87. The method of claim 86, wherein the administered composition elicits an immune response in the subject.

88. 88. The method of any one of claims 84-87, wherein the administered composition induces the production of one or more pro-inflammatory molecules in the subject.

89. 89. The method of claim 88, wherein the one or more proinflammatory molecules comprise interferon gamma (IFNγ), a cytokine, TNF-α, GM-CSF, MIP1α, granzyme B, granzyme A, perforin, or any combination thereof.

90. 90. The method of any one of claims 84-89, wherein the subject has previously been treated with one or more therapies and has developed at least partial resistance to said one or more therapies.

91. 91. The method of claim 90, wherein at least one of the one or more therapeutic agents comprises a small molecule.

92. 92. The method of any one of claims 84 to 91, wherein the condition is a proliferative disease, an inflammatory disease, an autoimmune disease, or a microbial infection.

93. 93. The method of any one of claims 84 to 92, wherein the subject has or is suspected of having a health condition associated with a proliferative disease, an inflammatory disease, an autoimmune disease, or a microbial infection.

94. The method of any one of claims 92 to 93, wherein the proliferative disease is cancer.

95. 95. The method of claim 94, wherein the cancer is breast cancer.

96. 96. The method of any one of claims 84 to 95, wherein the composition is administered to the subject individually as a sole therapy (monotherapy) or as a first therapy in combination with at least one additional therapy.

97. 97. The method of claim 96, wherein the at least one additional therapy is selected from the group consisting of chemotherapy, radiation therapy, immunotherapy, hormone therapy, toxin therapy, targeted therapy, and surgery.

98. 1. A kit for inducing a pharmacodynamic effect, for eliciting an immune response, and / or for the prevention and / or treatment of a condition, comprising: a) the self-amplifying RNA construct of claim 52; b) a nucleic acid according to claim 53; c) a recombinant cell according to any one of claims 54 to 63; and d) a pharmaceutical composition according to any one of claims 65 to 83; A kit comprising one or more of the following:

Citation Information

Patent Citations

  • Alphavirus replicon vector system

    JP2005508159A

  • Alphavirus vectors for respiratory pathogen vaccines

    JP2008500399A

  • Alphavirus replicon particles

    JP2021507713A

  • Lipid nanoparticles

    US20200222332A1

  • Alphavirus vector

    WO2014170493A2

Cited By

  • MRNA transcription skeleton vector and application thereof in preparation of self-amplification type mRNA vaccine

    CN120555511A